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Abstract
Many respiratory tract infections are treated with macrolide antibiotics. Regulatory agencies
warn that these antibiotics increase the risk of ventricular arrhythmia. This population-based
retrospective cohort study examined the 30-day risk of a hospital encounter with ventricular
arrhythmia and all-cause mortality in 503,612 matched pairs of older adults who received a
new outpatient prescription for an oral macrolide antibiotic and those prescribed referent
antibiotics from 2002 to 2013 in Ontario. Conditional logistic regression was used to measure
the association between macrolide exposure and outcomes. Macrolide antibiotics compared
with referent antibiotics were not associated with a higher 30-day risk of ventricular
arrhythmia (0.03% vs. 0.03%, relative risk [RR] 1.06, 95% confidence interval [CI] 0.831.36), and were associated with a lower risk of 30-day all-cause mortality (0.62% vs. 0.76%,
RR 0.82, 95% CI 0.78-0.86). These findings suggest that current warnings from Health
Canada and the U.S. Food and Drug Administration may be overstated.
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Chapter 1

1

Introduction

Macrolide antibiotics (e.g. azithromycin, clarithromycin and erythromycin) are a
common class of medications used to treat community-acquired respiratory tract
infections (1–4). In 2010, over 57 million outpatient prescriptions were written for
macrolide antibiotics in the United States (U.S.) (5). A recent observational study
prompted Health Canada and the U.S. Food and Drug Administration (FDA) to issue
warnings about the risk of QT interval prolongation and fatal ventricular arrhythmia with
azithromycin use (6,7). This study showed a higher risk of cardiovascular death and
all-cause mortality in patients prescribed azithromycin as compared with other antibiotic
prescriptions (amoxicillin) or antibiotic non-use (8). Findings from this study were
supported by prior case reports and published studies (9–15).
Other recent studies suggest these regulatory warnings may be overstated (16–19).
Mortensen et al. showed the risk of 90-day mortality was no higher (and rather was
lower) in older patients who received azithromycin compared with other guidelineconcordant antibiotics (16). In the same study, there was no difference between the two
groups in the risk of arrhythmia, heart failure or any cardiac event. Another study showed
no higher 5-day risk of cardiovascular death with azithromycin compared with
penicillin V (17). In a study of patients with radiologically confirmed communityacquired pneumonia, clarithromycin compared with antibiotic non-use was associated
with a higher risk of cardiovascular events, but not cardiovascular mortality or all-cause
mortality (18).
Given these conflicting findings, we conducted this large propensity-matched populationbased cohort study of older adults in the outpatient setting to investigate whether
azithromycin, clarithromycin or erythromycin compared with non-macrolide referent
antibiotics (amoxicillin, cefuroxime or levofloxacin) is associated with higher 30-day
risks of ventricular arrhythmia and all-cause mortality.
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Chapter 2

2

Literature Review

2.1 Outpatient macrolide antibiotic prescribing
Community-acquired respiratory tract infections are common and potentially serious,
especially in older adult patients and those with significant comorbidities (3). Macrolide
antibiotics, such as azithromycin, clarithromycin and erythromycin, are often used in the
treatment of such infections (4).
In Canada and the U.S., influenza and pneumonia were the eighth leading cause of death
in 2011 (20,21). In 2013, over $20 million was spent on outpatient macrolide
prescriptions in Canada (2). In 2010, over 57 million outpatient prescriptions were
written for macrolide antibiotics in the United States (5).

2.2 Mechanism of macrolide antibiotic action
Azithromycin and clarithromycin are derivatives of the older macrolide, erythromycin,
although the mechanism of action of all three macrolides is similar. They bind reversibly
to the 50S subunit of bacterial ribosomes, leading to inhibition of transpeptidation,
translocation, chain elongation and bacterial protein synthesis (22,23). Macrolides are
actively concentrated within leukocytes and are transported directly into the site of
infection (24). Azithromycin and clarithromycin are more acid stable than erythromycin,
providing improved oral absorption, tolerance, pharmacokinetic properties and a broader
spectrum of antibacterial activity than erythromycin (22,23).
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2.3 Mechanism of macrolide-induced QT interval
prolongation
The repolarization phase of cardiac muscle cells (myocytes) is driven predominantly by
outward movement of potassium ions (K+). The rapid delayed rectifier current (IKr) is an
important K+ current participating in ventricular repolarization (25). Blockade of this
outward potassium current can prolong the cardiac action potential (25,26). Macrolide
antibiotics are known to interfere with the IKr current, which results in accumulation of
K+ in cardiac myocytes thereby delaying cardiac repolarization (26–28). This disturbance
of myocardial repolarization is characterized by a prolonged QT interval on the
electrocardiogram (ECG) known as long QT syndrome (LQTS) (29,30). LQTS is
associated with an increased risk of cardiac arrhythmia referred to as torsades de pointes
(31,32). The primary symptoms in patients with LQTS include palpitations, syncope,
seizures and sudden cardiac death. This disorder may be either genetic or acquired
(33,34).
Erythromycin was the first macrolide to be associated with QT interval prolongation, but
subsequent reports and studies have also described QT interval prolongation with
azithromycin and clarithromycin use (14,15,35).

2.4 Search strategy and quality assessment of prior studies
We searched both MEDLINE (inception to June 2015) and Google Scholar (inception to
June 2015) for relevant articles to include in our literature review. The purpose of our
literature search was to identify prior studies that examined the association between
macrolide antibiotic use and the outcomes of ventricular arrhythmia and mortality. For
both databases, the final search strategy consisted of keywords such as macrolide,
antibiotic, arrhythmia, mortality, respiratory tract infection, pneumonia, azithromycin,
clarithromycin and erythromycin. We also used the related articles option in Google
Scholar to search for additional articles and searched relevant review articles and
reference lists of included articles.
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Inclusion and exclusion criteria were developed a priori. Studies were included if they
met the following criteria: (1) full-text English article, (2) randomized controlled trial
(RCT) or cohort study, (3) more than 1,000 patients, (4) mean age 18 years or more and
(5) reported ventricular arrhythmia (including composite outcomes) or mortality (allcause or cardiovascular). We excluded the following studies from our review: (1) no
incidence of main outcomes (ventricular arrhythmia or mortality) reported and (2)
insufficient information on the antibiotic exposure. Ten studies were identified as
meeting our inclusion criteria. For purposes of our literature review, the term ‘antibiotic
non-use’ refers to no antibiotic use of any kind.
We evaluated the quality of individual studies using the Downs and Black quality
assessment method, which is a list of 27 criteria to evaluate both randomized and nonrandomized trials (Appendix A) (36). This scale assesses the completeness and clarity of
study reporting, external validity, internal validity (e.g. bias and confounding) and power.
The tool was modified slightly for use in our review. Specifically, the scoring for
question 27 dealing with statistical power was simplified to a choice of awarding either 1
or 0 points depending on whether there was sufficient power to detect a clinically
important effect. On the modified scale, we gave all included studies a score from 0 to
28, grouped into the following four quality levels: excellent (26 to 28), good (20 to 25),
fair (15 to 19) and poor (14 or less).
Two reviewers (M.T. and R.J.) independently assessed the quality of the included
articles. Discrepancies between the two reviewers were resolved through re-evaluation
and discussion. We did not perform a meta-analysis because the studies were too
heterogeneous.

2.5 Summary of previous literature
The findings of ten published studies (summarized in Table 1) describing the risk of
ventricular arrhythmia or death with macrolide antibiotic use compared with other classes
of antibiotics or antibiotic non-use are inconsistent. These studies vary in patient age, sex
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and comorbidity. Our assessment of study quality using the Downs and Black quality
checklist determined that six of the reviewed studies were of fair quality (8–10,16,18,37)
and four were of good quality (11,12,17,19).

2.6 Macrolide antibiotics and risk of ventricular arrhythmia
One study included in our literature review reported an increased risk of 7-day ventricular
arrhythmia with azithromycin use compared to amoxicillin-clavulanate treatment (odds
ratio [OR] 4.32, 95% confidence interval [CI] 2.95-6.33) though the authors found no
such risk with clarithromycin (OR 0.72, 95% CI 0.48-1.08) (12).
Despite multiple case reports demonstrating evidence of QT prolongation with macrolide
antibiotic use (13–15), two studies included in our literature review reported no
significant increase in the risk of ventricular arrhythmia associated with macrolide use
relative to other antibiotics (9,16). Rao et al. found no statistically different risk of
arrhythmia with azithromycin compared with amoxicillin within 6 to 10 days (hazard
ratio [HR] 1.37, 95% CI 0.91-2.05), though an increased risk was observed within 5 days
of follow-up (HR 1.77, 95% CI 1.20-2.62) (9). Similarly, Mortensen et al. found no
significantly different 90-day risk of cardiac arrhythmia when comparing azithromycin
with other antibiotic use (OR 0.99, 95% CI 0.95-1.02) (16). The seven remaining studies
did not examine arrhythmia risk (8,10,11,17–19,37).

2.7 Macrolide antibiotics and risk of all-cause mortality
Two studies included in our literature review reported a higher risk of all-cause mortality
with macrolide antibiotic use (8,11) while four other studies reported no risk or a
decreased risk of death from any cause (9,16,18,19). In an RCT of five Copenhagen
cardiology departments, clarithromycin use relative to antibiotic non-use was associated
with an increased risk of all-cause mortality during three years of follow-up (HR 1.27,
95% CI 1.03-1.54) (11). Ray et al. found an increased 5-day risk of death from any cause
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when comparing azithromycin with antibiotic non-use (HR 1.85, 95% CI 1.25-2.75) and
amoxicillin (HR 2.02, 95% CI 1.24-3.30) (8).
A population-based prospective cohort study of 2,779 outpatients with communityacquired pneumonia assessed at seven Emergency Departments in Edmonton, Alberta
found significantly lower 30-day mortality in patients receiving macrolides compared to
another antibiotic (fluoroquinolone) (OR 0.28, 95% CI 0.09-0.86) (19). Three
observational studies showed no risk or a decreased risk of all-cause mortality when
comparing macrolides to other classes of antibiotics or antibiotic non-use at 6 to10 days
(HR 1.14, 95% CI 0.81-1.62) (9), 30 days (OR 0.76, 95% CI 0.73-0.80) (16), 90 days
(OR 0.73, 95% CI 0.70-0.76) (16) and one year of follow-up (HR 1.13, 95% CI 0.851.51) (18).

Table 1. Literature summary of ten published studies describing cardiovascular events and mortality associated with macrolide use
compared with other classes of antibiotics or antibiotic non-use for the treatment of respiratory tract infections
Study Type /
Patient Description
Randomized Controlled Trials
Jespersen
-Five Copenhagen
University cardiology
et al.,
departments and a
2006 (11)
coordinating centre
-2,172 participants who had
a discharge diagnosis of MI
or angina pectoris from 1993
to 1999 randomized to
clarithromycin (mean age
65.4 years) and 2,200 to
placebo (mean age 65.2
years)
Author

Population-Based Studies
Asadi et
-Population-based
prospective cohort study of
al., 2012
2,779 outpatients with
(19)
community-acquired
pneumonia assessed at 7
Emergency Departments in
Edmonton, Alberta, Canada
prescribed macrolide (mean
age 46.1 years) or
fluoroquinolone (mean age
61.9) enrolled from
2000 to 2002 and followed
until 2007

Potential Risk
Factors

Dose / Exposure Time /
Study Limitations

Quality
Scorea

-Clarithromycin group: n = 2,172; placebo
group: n = 2,200
-No significant effects of clarithromycin on
the primary outcome (344 [15.8%] vs. 307
[13.8%], HR 1.15, 95% CI 0.99-1.34) or
secondary outcome (249 [11.5%] vs. 218
[9.9%], HR 1.17, 95% CI 0.98-1.40)
-All-cause mortality (212 [9.8%] vs. 172
[7.8%], HR 1.27, 95% CI 1.03-1.54) and CV
mortality (111 [5.1%] vs. 78 [3.5%], HR 1.45,
95% CI 1.09-1.92) were significantly higher
in the clarithromycin arm

-Age, sex,
previous CV
disease and risk
factors,
smoking status,
concurrent use
of certain drugs

-Two-week treatment with
clarithromycin 500 mg/day or
matching placebo; follow-up period
2-3 years
-Primary outcome: composite of
all-cause mortality, MI or unstable
angina pectoris during 3-year
follow-up; Secondary outcome:
composite of CV mortality, MI or
unstable angina pectoris
-Limitation: more smokers were
randomized to the clarithromycin
arm
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-Macrolide group: n = 1,832; fluoroquinolone
group: n = 947
-30-day mortality was significantly lower in
the macrolide group relative to the
fluoroquinolone group (4 [0.2%] vs. 25 [3%],
adjusted OR 0.28, 95% CI 0.09-0.86)

-Age, sex,
clinical
radiographic
severity of
illness at
presentation,
nursing home
status

-10 days of any one of the
following: doxycycline 200 mg
initially then 100 mg/day,
levofloxacin 500 mg/day,
azithromycin 500 mg initially then
250 mg/day, clarithromycin 500
mg/day or erythromycin 500
mg/day
-Limitations: confounding by
indication, physician bias, no postdischarge microbiologic data
available, generalizability

20

Observations
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Chou et
al., 2015
(12)

-Retrospective cohort study
of Taiwan National Health
Insurance data comparing
patients prescribed oral
amoxicillin-clavulanate
(mean age 43.9 years),
azithromycin (mean age 44.7
years), clarithromycin (mean
age 47.1 years),
ciprofloxacin (mean age 46.9
years), levofloxacin (mean
age 50.6 years) or
moxifloxacin (mean age 52.3
years) between January 2001
and November 2011

Mortensen
et al.,
2014 (16)

-Retrospective cohort study
of VA data comparing
31,863 patients hospitalized
with pneumonia from 2002
to 2012 prescribed
azithromycin (mean age 77.8
years) to 31,863 patients who
received other guidelineconcordant antibiotics (mean
age 77.8 years)

Rao et al.,
2014 (9)

-Retrospective cohort study
of US veterans (mean age
56.5 years) who received an
outpatient prescription of

-Amoxicillin-clavulanate users: n =
1,102,358; azithromycin users: n = 66,745;
clarithromycin users: n = 393,243;
ciprofloxacin users: n = 205,205; levofloxacin
users: n = 117,352; moxifloxacin users: n =
38,833
-Compared with amoxicillin-clavulanate
treatment, the use of azithromycin was
associated with significantly higher 7-day
risks of ventricular arrhythmia (OR 4.32, 95%
CI 2.95-6.33) and CV death (OR 2.62, 95%
CI 1.69-4.06)
-Compared with amoxicillin-clavulanate
treatment, the use of clarithromycin was
associated with similar 7-day risk of
ventricular arrhythmia (OR 0.72, 95% CI
0.48-1.08) and decreased risk of CV death
(OR 0.51, 95% CI 0.33-0.80)
-Azithromycin users: n = 31,863; nonazithromycin users: n = 31,863
-90-day mortality significantly lower in the
azithromycin group (17.4% vs. 22.3%, OR
0.73, 95% CI 0.70-0.76)
-30-day mortality significantly lower in the
azithromycin group (OR 0.76, 95% CI 0.730.80)
-Significantly increased odds of 90-day MI
(5.1% vs. 4.4%, OR 1.17, 95% CI 1.08-1.25)
but not any cardiac event (43.0% vs. 42.7%,
OR 1.01, 95% CI 0.98-1.05), cardiac
arrhythmias (25.8% vs. 26.0%, OR 0.99, 95%
CI 0.95-1.02) or heart failure (26.3% vs.
26.2%, OR 1.01, 95% CI 0.97-1.04)
-During treatment days 1 to 5, patients
receiving azithromycin had significantly
increased risk of death (HR 1.48, 95% CI
1.05-2.09) and serious arrhythmia (HR 1.77,

-Age, sex,
calendar date,
concomitant
medications,
health resource
utilization,
indications for
antibiotic use

-Limitations: interethnic differences
and generalizability, reliance on
ICD-9 codes, true incidence of TdP
unknown, residual confounding,
confounding by indication, precise
risk estimates for subgroups of
patients with certain characteristics
could not be determined
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-Tobacco use,
alcohol use,
liver disease,
multiple classes
of medications,
SES, race

-At least 1 outpatient medication
from a VA pharmacy within 90
days prior to admission; at least 1
dose of antimicrobial therapy
within the first 48 hours of
admission
-Limitations: few female patients,
only patients 65 and older, reliance
on ICD-9 diagnosis of CV events
rather than clinical information,
ICD-9 codes not validated in VA
administration data, undetermined
duration of azithromycin therapy
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-Race, age, sex,
indication for
antibiotics
cardiac

-Follow-up times were separated
into the first 5 days and days 6
through 10 after antibiotics were
dispensed, with day 1 being the first

18

8

Ray et al.,
2004 (10)

Ray et al.,
2012 (8)

either amoxicillin (n =
979,380), azithromycin (n =
594,792) or levofloxacin (n =
201,798) between September
1999 and April 2012

95% CI 1.20-2.62) compared with patients
receiving amoxicillin
-On treatment days 6 to 10, when comparing
azithromycin with amoxicillin, risks were not
statistically different for death from any cause
(HR 1.14, 95% CI 0.81-1.62) and arrhythmia
(HR 1.37, 95% CI 0.91-2.05)

morbidities,
laboratory
findings,
medication

-Retrospective cohort study
of Tennessee Medicaid
patients between January
1988 and December 1993
-5,305 person-years of
current use of erythromycin
(mean age 41.4 years) and
111,779 person-years of
former use (mean age 42.2
years) compared to
1,126,013 person-years of
antibiotic non-use (mean age
45.0 years) and 6,846
person-years of current use
of amoxicillin (mean age
41.7 years)
-Retrospective cohort study
of Tennessee Medicaid
patients between 1992 and
2006 comparing patients
who took azithromycin
(347,795 prescriptions, mean
age 48.6 years), no
antibiotics (1,391,180
prescriptions, mean age 48.6
years), amoxicillin
(1,348,672 prescriptions,
mean age 47.7 years),
ciprofloxacin (264,626

-Rate of sudden death from cardiac causes
was twice as high among current users of
erythromycin compared to antibiotic nonusers (10 vs. 1,358 deaths, adjusted incidencerate ratio 2.01, 95% CI 1.08-3.75)
-No significant increase for former users of
erythromycin (100 vs. 1,358 deaths, adjusted
incidence-rate ratio 0.89, 95% CI 0.72-1.09)
or current users of amoxicillin (8 vs. 1,358
deaths, adjusted incidence-rate ratio 1.18,
95% CI 0.59-2.36)

-Smoking,
higher BMI,
high
consumption of
saturated fats,
lack of physical
activity, preexisting CV
disease (heart
failure, angina
and MI),
concurrent use
of CYP3A4
inhibitors

-Increased risk of 5-day CV death (HR 2.88,
95% CI 1.79-4.63) and death from any cause
(HR 1.85, 95% CI 1.25-2.75) from
azithromycin (adjusted) relative to no
antibiotics (adjusted)
-Relative to amoxicillin (unadjusted),
azithromycin (adjusted) was associated with
an increased risk of CV death (HR 2.49, 95%
CI 1.38-4.50) and death from any cause (HR
2.02, 95% CI 1.24-3.30)
-Among patients who took azithromycin,
there were 29 CV deaths during the 5-day
course of treatment (85.2 per 1 million

-CV disease
and other
behavioural risk
factors
associated with
CV disease,
indication for
antibiotic
therapy

day the drug was dispensed
-Azithromycin, levofloxacin or
amoxicillin (including amoxicillin
with clavulanate potassium) within
30 days after a VA outpatient visit
-Limitations: residual confounding,
baseline differences between
antibiotic groups, exclusion criteria
-Current use: days of
supply from the day the
prescription was filled; antibiotic
non-use: no use of any study
antibiotics within the previous 365
days; former use: some use of a
study medication that was not
current but had occurred within the
previous 365 days
-Limitations: drug compliance, no
information on a number of
behavioural risk factors

-Duration of treatment: 5-day
period generally recommended for
azithromycin and 10-day period
most commonly suggested for other
study antibiotics
-Limitation: misclassification
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prescriptions, mean age 50.5
years) or levofloxacin
(193,906 prescriptions, mean
age 51.5 years)

Schembri
et al.,
2013 (18)

Svanstrom
et al.,
2013 (17)

-Secondary analysis of a
prospectively collected
dataset of 1,631 patients
admitted to NHS Lothian
Hospitals in Edinburgh, UK
with radiologically
confirmed communityacquired pneumonia and
prescribed clarithromycin
(median age 65 years)
compared with patients who
received non-macrolide
antibiotics (median age 68
years) during their admission
between 2005 and 2009
-Retrospective cohort study
of Danish adults comparing
1,102,050 episodes of
azithromycin use (mean age
39.7 years) with no use of
antibiotic (mean age 39.5
years) matched in a 1:1 ratio
and comparing 1,102,419
episodes of azithromycin use
(mean age 39.7 years) with
7,364,292 episodes of

courses); for those not taking antibiotics, there
were 41 CV deaths (29.8 per 1 million
periods); for the amoxicillin group, there were
42 CV deaths (31.5 per 1 million courses)
-Risk of CV death significantly greater with a
5-day course of azithromycin (adjusted) than
with the first 5 days of a course of
ciprofloxacin (unadjusted HR 3.49, 95% CI
1.32-9.26) but not significantly different from
levofloxacin (unadjusted HR 1.27, 95% CI
0.66-2.47)
-Clarithromycin users: n = 980; nonmacrolide users: n = 651
-Significant association between
clarithromycin use and CV events compared
with non-macrolide users after propensity
matching (123 [12.6%] vs. 48 [7.4%], HR
1.58, 95% CI 1.08-2.30)
-Clarithromycin use was not associated with a
significant difference in all-cause mortality
(adjusted HR 1.13, 95% CI 0.85-1.51) or CV
mortality (adjusted HR 1.58, 95% CI 0.932.71)

-With propensity score matched analysis, risk
of death from CV causes significantly
increased with current use of azithromycin as
compared with no use of antibiotics (rate ratio
2.85, 95% CI 1.13-7.24)
-With adjustment for propensity scores,
current azithromycin use was not associated
with an increased risk of CV death when
compared with penicillin V (rate ratio 0.93,
95% CI 0.56-1.55)

-Age, history of
CV events

-Age, sex,
history of CV
disease

-Macrolide users included all
patients who received at least one
dose of clarithromycin during their
hospital admission
-Duration of use: < 3 days, 3-6
days, 7 days, > 7 days
-1-year follow-up
-Limitations: bias due to
unrecorded factors, patients with
more severe illness were more
likely to be prescribed
clarithromycin and thus
clarithromycin may be a marker for
more severe infection and hence
increased CV events
-Current use (1-5 days), recent use
(6-10 days) and past use (11-35
days)
-Limitations: no information on the
indication for treatment and several
known risk factors (e.g. smoking
and BMI), primary definition,
including all CV causes of death,
was broad
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penicillin V use (mean age
42.0 years) between 1997
and 2010
Svanstrom
et al.,
2014 (37)

-Retrospective cohort study
of Danish adults who
received prescriptions for
clarithromycin (n = 108,767,
mean age 57.2 years),
roxithromycin (n = 350,575,
mean age 56.6 years) or
penicillin V (n = 1,519,324,
mean age 55.7 years)

-Compared with use of penicillin V (235
deaths, incidence rate 2.5 per 1,000 person
years), use of clarithromycin was associated
with a significantly increased risk of cardiac
death (18 deaths, incidence rate 5.3 per 1,000
person years, adjusted rate ratio 1.76, 95% CI
1.08-2.85) but use of roxithromycin was not
(32 deaths, incidence rate 2.5 per 1,000
person years, adjusted rate ratio 1.04, 95% CI
0.72-1.51)

-Sex, age,
cardiac risk
score,
concomitant
use of
cytochrome
P450 3A
inhibiting drugs

-Treatment: 7-day course of
antibiotic
-Limitations: lack of information on
lifestyle and health factors known
to influence the risk of cardiac
death (e.g. smoking and BMI),
missing infection information,
limited power to detect difference
in subgroup analyses
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Abbreviations: BMI = body mass index, CI = confidence interval, CV = cardiovascular, HR = hazard ratio, ICD-9 = International Classification of Diseases,
Ninth Revision, IL = interleukin, MI = myocardial infarction, NHS = National Health Service, OR = odds ratio, SES = socioeconomic status, TdP = torsades de
pointes, TNF = tumour necrosis factor, VA = Department of Veterans Affairs
a
We evaluated the quality of individual studies using the Downs and Black quality assessment method, which is a list of 27 criteria to evaluate both randomized
and non-randomized trials (Appendix A) (36). This scale assesses the completeness and clarity of study reporting, external validity, internal validity (e.g. bias and
confounding) and power. The tool was modified slightly for use in our review. Specifically, the scoring for question 27 dealing with statistical power was
simplified to a choice of awarding either 1 or 0 points depending on whether there was sufficient power to detect a clinically important effect. On the modified
scale, we gave all included studies a score from 0 to 28, grouped into the following four quality levels: excellent (26 to 28), good (20 to 25), fair (15 to 19) and
poor (14 or less).
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Chapter 3

3

Rationale and Research Questions

3.1 The need for research
In 2013, Health Canada and the U.S. FDA warned about a higher risk of QT interval
prolongation and subsequent ventricular arrhythmia among patients taking azithromycin
(6,7). Although many case reports support this assertion (13–15,27), evidence from
published studies is inconsistent (8–12,16–19,37). To better elucidate the safety profiles
of macrolide antibiotics in the treatment of community-acquired respiratory tract
infections, we conducted a population-based cohort study to investigate the risks of
ventricular arrhythmia and all-cause mortality associated with azithromycin,
clarithromycin or erythromycin use compared with other antibiotics for similar
indications.

3.2 Research questions and hypotheses
3.2.1

Primary research question

In the outpatient setting, does a group of patients prescribed macrolide antibiotics
compared with a group of patients prescribed non-macrolide antibiotics that have similar
baseline characteristics have an altered 30-day risk of a hospital encounter with
ventricular arrhythmia?
Hypothesis: Based on prior literature, macrolide antibiotic use may be associated with a
higher risk of ventricular arrhythmia compared with non-macrolide antibiotic use.
However, based on other prior literature, it is also possible that there will be no difference
in risk between the two groups.
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3.2.2

Secondary research questions

1) In the outpatient setting, does a group of patients prescribed macrolide antibiotics
compared with a group of patients prescribed non-macrolide antibiotics that have
similar baseline characteristics have an altered 30-day risk of all-cause mortality?
Hypothesis: Based on prior literature, macrolide antibiotic use may be associated
with a higher risk of all-cause mortality compared with non-macrolide antibiotic use.
However, based on other prior literature, it is also possible that there will be no
difference in risk between the two groups.
2) In older adults in the outpatient setting, in subgroup analyses is the association
between macrolide antibiotic use (compared with non-macrolide antibiotic use) and
30-day risk of a hospital encounter with ventricular arrhythmia modified in the
presence of conditions that can be responsible for ventricular arrhythmia? These four
conditions are (1) chronic kidney disease, (2) congestive heart failure, (3) coronary
artery disease and (4) concurrent use of a drug known to prolong the QT interval.
Hypothesis: Compared with non-macrolide antibiotic use, macrolide antibiotic use
will be associated with a higher risk of ventricular arrhythmia when the conditions
that can be responsible for ventricular arrhythmia are present.
3) In older adults in the outpatient setting, in subgroup analyses is the association
between macrolide antibiotic use (compared with non-macrolide antibiotic use) and
30-day risk of all-cause mortality modified in the presence of conditions that can be
responsible for mortality? These four conditions are (1) chronic kidney disease, (2)
congestive heart failure, (3) coronary artery disease and (4) concurrent use of a drug
known to prolong the QT interval.
Hypothesis: Compared with non-macrolide antibiotic use, macrolide antibiotic use
will be associated with a higher risk of all-cause mortality when the conditions that
can be responsible for mortality are present.

14

Chapter 4

4

Methods

4.1 Study design and setting
We conducted a population-based retrospective cohort study of older adults from
April 1, 2002 to March 1, 2013 using linked healthcare databases in Ontario, Canada.
Ontario has approximately 13.7 million residents, 16% of whom are 65 years of age or
older (38). The Ontario Health Insurance Plan (OHIP) is the single payer for all Ontario
citizens and provides universal access to hospital care and physician services. Those aged
65 years or older (approximately 2 million residents) also receive prescription drug
coverage.
Ontario’s administrative healthcare databases provide a rich source of information and
are representative of the entire province. The use of these databases addresses problems
typical of prospective studies, such as selection and information biases, and allow for
large sample sizes and long periods of follow-up. Emigration out of Ontario is less than
1% per year, with little loss to follow-up (39).
We conducted this study at the Institute for Clinical Evaluative Sciences (ICES)
according to a pre-specified protocol that was approved by the Research Ethics Board at
Sunnybrook Health Sciences Centre (Toronto, Ontario). Participant informed consent
was not required for this study. The reporting of this study followed the Strengthening the
Reporting of Observational Studies in Epidemiology (STROBE) guidelines (see
Appendix B) (40).
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4.2 Data sources
We used the following 11 healthcare administrative databases housed at ICES to
ascertain patient characteristics, drug exposure, covariate information and outcome data.
These datasets were linked using unique, encoded identifiers and analyzed at ICES.
Registered Persons Database of Ontario (RPDB): We used RPDB to obtain information
on patient demographics (age, sex and vital status), income (categorized into quintiles of
average neighbourhood income) and location of residence (urban or rural). Moreover, we
used the vital status information captured by this database to ascertain the outcome of
all-cause mortality.
Ontario Drug Benefit (ODB) Database: The ODB database stores records for all
outpatient drug prescriptions dispensed to patients aged 65 years and older in Ontario
with a high level of accuracy (overall error rate of less than 1%) (41). We used this
database to ascertain exposure to macrolide antibiotics and baseline medication use
assessed in the 120 days prior to cohort entry. We also acquired information on patient
residential status (community-dwelling or long-term care) and medical specialty of the
physicians who prescribed study antibiotics.
Canadian Institute for Health Information Discharge Abstract Database and National
Ambulatory Care Reporting System (CIHI-DAD, NACRS): CIHI-DAD and NACRS
contain diagnostic and procedural information on all inpatient, emergency department
and outpatient visits occurring in Ontario. The hospital diagnosis codes were based on the
International Classification of Diseases, Ninth Revision (ICD-9) codes prior to 2002 and
Tenth Revision (ICD-10) codes since 2002. We used both ICD-9 and ICD-10 codes to
determine baseline comorbidities in the five years prior to receipt of the new antibiotic
prescription (detailed in Appendix C). We used ICD-10 codes exclusively to determine
hospitalized outcomes since all events occurred after the implementation of this coding
system (detailed in Appendix D).
Ontario Health Insurance Plan (OHIP) Database: The OHIP database contains
information on physician claims for inpatient and outpatient services using fee codes. We
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used the information captured by this database to identify baseline comorbid conditions
in addition to the diagnostic information obtained from CIHI-DAD.
Canadian Organ Replacement Register (CORR): This registry stores information on
renal replacement therapies. CORR receives data from the Ontario Renal Network,
Trillium Gift of Life Network and independent sources. We used this database to identify
the number of kidney transplants occurring in our cohort for the comorbidity of chronic
kidney disease.
Ontario Mental Health Reporting System (OMHRS) Database: The OMHRS database
contains demographic and health information on patients admitted to adult mental health
beds in Ontario. Diagnosis codes for health conditions based on the Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition are recorded in this database (detailed
in Appendix C). In addition to the CIHI-DAD and OHIP databases, we used the
diagnostic information stored in this database to determine baseline psychiatric comorbid
conditions.
Institute for Clinical Evaluative Sciences Physician Database (IPDB): IPDB reports
prescriber and specialist referral data including demographics, education, location and
measures of physician activity. We used this database to measure the number of general
practitioner visits and nephrologist and cardiologist consults.
Ontario Registrar General Vital Statistics Database (ORGD): ICD-9 codes were used to
ascertain cause of death in ORGD (see Appendix E). New variables that are coded in the
database as ICD-10 are converted to ICD-9 codes to ensure consistency across all years.
Cerner and Gamma-Dynacare Laboratory Databases: A subpopulation of patients in
Southwestern Ontario had outpatient serum creatinine and urine dipstick protein
measurements available before cohort entry and was in the catchment area of 12 hospitals
in which linked serum creatinine laboratory measurements were available through these
laboratory datasets. We used the information to assess baseline kidney function.
All 11 databases have been used previously to study adverse drug events and health
outcomes (42–51).
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4.3 Patients
We established a cohort of older adults in Ontario who were dispensed a new outpatient
prescription for a macrolide antibiotic (azithromycin, clarithromycin or erythromycin)
between April 1, 2002 and March 1, 2013. The date of the prescription served as the
index date (referred to as the cohort entry date or start time for follow-up).
Inherent to observational drug studies is a bias known as confounding by indication. This
bias occurs when drugs are selectively used or not used by those who developed the
outcome of interest (52). The assumption is that patients are exposed to drugs for
particular reasons and the variables underlying these reasons may predispose patients to
study outcomes of interest. A method to limit confounding by indication is to compare
treatments that are interchangeable within the same indication (53). Therefore, we
compared our macrolide antibiotic users to a group of older adults with similar indicators
of baseline health who were prescribed non-macrolide antibiotics (amoxicillin,
cefuroxime or levofloxacin).
Before matching, we excluded the following patients from both groups: (1) those who
were in their first year of eligibility for prescription drug coverage (aged 65 years) to
avoid incomplete medication records, (2) those with prescriptions for any antibiotic in the
180 days prior to the index date to ensure that the drug was newly prescribed, (3) those
who received a prescription for more than one type of antibiotic on the index date (in
order to form mutually exclusive groups), (4) those who were discharged from the
hospital in the two days prior to their index date to ensure these were new outpatient
antibiotic prescriptions (because in Ontario, patients continuing an antibiotic treatment
initiated in the hospital would have their outpatient antibiotic prescription dispensed on
the same day or the day after hospital discharge) and (5) those with daily drug doses that
were not standard for the treatment of respiratory tract infections to ensure
generalizability to usual prescribing (see Appendix F). Study patients could only enter the
cohort once, so for patients with multiple eligible prescriptions, we restricted the
information to the first eligible prescription.
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4.4 Matching
We used propensity score matching to eliminate systematic differences in the measured
baseline characteristics of our comparison groups. This allowed us to form a matched set
of patients in our two groups with a similar probability of receiving a macrolide antibiotic
given a set of measured baseline covariates (54,55). We estimated the propensity scores
using a multivariable logistic regression model with 106 baseline characteristics selected
because of their potential influence on the outcomes or segregation of patients between
the comparison groups (Appendix G) (55–57). Subsequently, we matched a referent user
to each macrolide antibiotic user on the following six characteristics: the logit of the
propensity score (within calipers of width ± 0.2 standard deviations) (58), chronic kidney
disease (yes or no), congestive heart failure (yes or no), coronary artery disease (yes or
no), QT-prolonging drug use (yes or no) and availability of serum creatinine
measurement in the year prior to the index date (yes or no). There are several types of
matching techniques including individual matching and frequency matching (59). In
greedy matching, a macrolide antibiotic user is first selected at random and then matched
to the nearest non-macrolide antibiotic user, even if that non-user would have been a
better match for a subsequent macrolide antibiotic user. This process is then repeated
until non-macrolide antibiotic users have been matched to all macrolide antibiotic users
or until the list of macrolide antibiotic users for whom a matched non-macrolide
antibiotic user can be found has been exhausted (55). An alternative to greedy matching
is optimal matching, in which matches are formed to minimize the total within-pair
difference of the propensity score (60). In studies involving large administrative
healthcare databases, greedy matching is simpler to implement and considerably faster to
run. Additionally, it has been shown that optimal matching does not perform better than
greedy matching in forming balanced groups (61). For these reasons, we selected the
greedy matching technique. Study patients were matched without replacement. Those
who were not matched successfully were excluded from our analysis.
We anticipated the 106 variables used in this study to be complete. We expected
prescriber information would be missing in up to 25% of patients based on the results of
prior studies (42,46,51,62). For income quintile, we expected up to 0.5% of patients
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would have a missing value based on the results of prior studies (42,46,62), and missing
values in the unmatched cohort were re-classified into the average income quintile
(income quintile 3) during matching. For location of residence, we expected up to 0.2%
of patients would have a missing value based on the results of prior studies (49,51), and
missing values in the unmatched cohort were re-classified into the "No" category during
matching.

4.5 Baseline characteristics
We assessed baseline comorbid conditions in the five years prior to the index date and
concurrent medication use in the 120 days prior to the index date of each macrolide
antibiotic user and referent non-macrolide antibiotic user (see Appendix C for coding
information). For the subpopulation of patients whose laboratory measurements were
available, we assessed their kidney function in the year prior to their index date. Chest xray, urinalysis and sputum tests were assessed in the seven days prior to cohort entry. We
evaluated prior health care use with physician visits, and diagnostic and screening tests
performed in the previous year.

4.6 Outcomes
The primary outcome of this study was a hospital encounter (presentation to the
emergency room or hospital admission) with ventricular arrhythmia (ventricular
tachycardia or ventricular fibrillation) in any diagnosis field. The secondary outcome was
all-cause mortality. We restricted our analysis to 30 days after the index date because
macrolide antibiotics are prescribed for short durations and any observed outcomes can
be reasonably attributed to our study drugs over this timeframe. Furthermore, QT interval
prolongation has been shown to start within hours to days of initiating macrolides, and
thus, one would expect that drug-related ventricular arrhythmias would occur soon after
initiating a macrolide antibiotic prescription (14,15,63–65).
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The diagnosis codes used to identify ventricular arrhythmia are presented in Appendix D.
Trained personnel enter these codes into the databases based only on physician-recorded
diagnoses in a patient’s medical chart. The ICD-10 codes for ventricular arrhythmia have
not been fully validated; however, we would expect their sensitivity to be low as true
ventricular arrhythmias frequently go undetected in routine healthcare (because they
often occur outside hospital settings, in unmonitored patients in hospital or in a setting of
multi-organ medical illness). In previous studies assessing the accuracy of ICD-9 and
ICD-10 codes for cardiac arrhythmia (ventricular and supraventricular), the positive
predictive value (PPV; truly have the condition when code present) exceeded 80% (66–
69). We performed a manual review of 202 charts in our region and confirmed a PPV of
92% (95% CI 87-95%) for the set of codes used in this study to detect ventricular
arrhythmia. All-cause mortality vital statistics are coded accurately in our data sources
with a sensitivity of 97.8% and specificity of 100% for the finding of death (70).

4.7 Statistical analyses
We compared baseline characteristics between those prescribed macrolide antibiotics and
those prescribed non-macrolide antibiotics using standardized differences. This metric
describes differences between group means relative to the pooled standard deviation and
is considered a meaningful difference if greater than 10% (71). The use of standardized
differences is preferred over statistical hypothesis testing (using P values) for assessing
balance in baseline characteristics between propensity score matched groups (72–74).
The standardized difference is not influenced by sample size and thus, one can compare
balance in the unmatched sample to that in the matched sample (73,74).
We estimated the OR and 95% CIs for the primary and secondary outcomes using
conditional logistic regression, which accounted for matching (75). The non-macrolide
antibiotic group was the referent group. Each OR was approximated to be the relative risk
(RR), which was appropriate given the incidences observed.
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We also evaluated the association between macrolide antibiotic and our outcomes in four
specified subgroups, defined by the presence or absence of the following conditions: (1)
chronic kidney disease, (2) congestive heart failure, (3) coronary artery disease and (4)
concurrent use of a drug known to prolong the QT interval (Appendix H). We
hypothesized that any RR of ventricular arrhythmia with macrolide antibiotic use
compared to referent antibiotic might be greater when these conditions were present than
when they were absent. For example, the dose of clarithromycin should be reduced by
50% in chronic kidney disease due to impaired clearance, but in practice this seldom
occurs (76). Similarly, in prior reports, ventricular arrhythmia with macrolide antibiotic
use frequently occurred in patients with pre-existing risk factors such as congestive heart
failure (77), cardiovascular disease (14,78–80) and those taking other QT-prolonging
medications (81,82). We determined interaction P values by including interaction terms
in the regression models.
Chronic kidney disease was identified using an algorithm of hospital diagnosis codes
validated in our region for older adults (83). The algorithm identified patients with a
median estimated glomerular filtration rate (eGFR) of 38 mL/min/1.73 m2 (interquartile
range [IQR] 27-52 mL/min/1.73 m2), whereas its absence identified patients with a
median eGFR of 69 mL/min/1.73 m2 (IQR 56-82 mL/min/1.73 m2). The algorithm for
chronic kidney disease had a sensitivity of 32% and specificity of 94% using an eGFR of
45 mL/min/1.73 m2 as the reference standard (83). Due to its limited sensitivity, the
algorithm underestimated the true prevalence of chronic kidney disease.
To provide insights for any observed difference in all-cause mortality between our two
groups, we also conducted a post hoc analysis to determine the various causes of death in
our matched cohort. Finally, we conducted an additional analysis of our outcomes at 14
days of follow-up rather than 30 days.
We conducted all analyses with SAS version 9.4 (SAS Institute, Cary, North Carolina,
2011). In all outcome analyses, we interpreted two-tailed P values less than 0.05 as
statistically significant.
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5

Results

5.1 Cohort characteristics
5.1.1

Unmatched cohort

Cohort selection is presented in Figure 1 and baseline characteristics before and after
matching are presented in Table 2. We identified 616,359 older adults with prescriptions
for macrolide antibiotics (azithromycin, clarithromycin or erythromycin) and 705,132
patients with prescriptions for the referent antibiotics (amoxicillin, cefuroxime or
levofloxacin) before matching. The mean age of the unmatched cohort was 73.9 years
and 56.7% were women.
Prior to matching, patients prescribed macrolide antibiotics compared to those prescribed
referent antibiotics were more likely to receive their prescription from a general
practitioner (77.0% vs. 56.6%), have chronic lung disease (28.8% vs. 23.8%), were less
likely to use warfarin (4.6% vs. 7.4%) and were less likely to have a urinalysis test (1.5%
vs. 4.9%) (Table 2). Information on income was not available for 2,160 (0.4%) macrolide
antibiotic users and 2,468 (0.4%) non-macrolide antibiotic users. Location of residence
could not be ascertained for 647 (0.1%) macrolide antibiotic users and 708 (0.1%)
non-macrolide antibiotic users. Local Health Integration Network (LHIN), which refers
to health authorities responsible for regional administration of public healthcare services
in Ontario, was unavailable for 619 (0.1%) macrolide antibiotic users and 684 (0.1%)
non-macrolide antibiotic users. Prescriber information was not available for 100,111
(16.2%) macrolide antibiotic users and 262,915 (37.3%) non-macrolide antibiotic users in
the unmatched cohort.
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5.1.2

Matched cohort

A total of 503,612 macrolide antibiotic users were successfully matched to 503,612
non-macrolide antibiotic users. The two groups were well-balanced and showed no
meaningful differences in the 106 measured baseline characteristics: age, sex, income,
year of cohort entry, location of residence, residential status, LHIN, prescribing
physician, 30 comorbid conditions, use of 37 medications, general practitioner visits,
nephrology consults, cardiology consults, 25 prior investigations and treatments, baseline
serum creatinine concentration, eGFR and urine dipstick protein (Table 2). The mean age
of the matched cohort was 74.0 years and 57.3% of patients were women. Clarithromycin
and azithromycin were the most frequently prescribed macrolide antibiotics (48.4% and
48.3%, respectively), followed by erythromycin (3.3%). The median starting daily dose
for clarithromycin was 1,000 mg (IQR 500 to 1,000 mg), for azithromycin was 300 mg
(IQR 300 to 300 mg) and for erythromycin was 1,000 mg (IQR 999 to 1,000 mg). The
median day supply for clarithromycin, azithromycin and erythromycin was 10 days (IQR
7 to 10 days), 5 days (IQR 5 to 5 days) and 7 days (IQR 7 to 10 days), respectively.
LHIN information was unavailable for 500 (0.1%) macrolide users and 480 (0.1%) nonmacrolide antibiotic users in the matched cohort. Prescriber information was not available
for 100,093 (19.9%) macrolide antibiotic users and 95,973 (19.1%) non-macrolide
antibiotic users in the matched cohort. General practitioners were the most frequent
prescribers (73.1%).

5.2 Main analysis
The primary and secondary outcomes are shown in Table 3. Across the entire cohort, in
the 30-day follow-up period, 260 patients (0.03%) had a record of a hospital encounter
with ventricular arrhythmia and 6,977 (0.69%) died.
The 30-day risk of ventricular arrhythmia with macrolide antibiotic use compared to
referent antibiotic use was not statistically different (0.03% vs. 0.03%, RR 1.06, 95% CI
0.83-1.36, P value 0.62). Macrolide antibiotic compared with referent antibiotic was
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associated with a lower 30-day risk of all-cause mortality (0.62% vs. 0.76%, RR 0.82,
95% CI 0.78-0.86, P value < 0.0001).

5.3 Subgroup analysis
Subgroup analyses for ventricular arrhythmia and all-cause mortality are shown in
Figures 2 and 3. The presence or absence of chronic kidney disease, congestive heart
failure, coronary artery disease or concurrent use of a QT-prolonging drug did not
significantly modify the relative association between antibiotic exposure and the risk of
ventricular arrhythmia (P values for interaction ranged from 0.28-0.80). Across all
subgroups, use of macrolide antibiotics compared to referent antibiotics was associated
with a lower risk of all-cause mortality, with no modification of the relative association
across subgroups (P values for interaction ranged from 0.11-0.67).

5.4 Additional analyses
First, using ORGD, we conducted a post hoc analysis to determine the various causes of
death in our matched cohort. Specific codes are listed in Appendix E. There were no
significant differences in the cause of death between the two groups. The most common
cause of 30-day mortality among older adults prescribed macrolide antibiotics was
cardiovascular disease (n = 638, 20.3% of deaths), followed by cancer (n = 569, 18.1%).
Among older adults prescribed referent antibiotics, the most common causes of death
were cancer (n = 785, 20.5%) and cardiovascular disease (n = 755, 19.7%) (Appendix I).
Second, we examined our outcomes at 14 days of follow-up. Similar to our 30-day
follow-up analysis, macrolide antibiotic use compared to referent antibiotic use was
associated with no different risk in ventricular arrhythmia (0.01% vs. 0.01%, RR 0.99,
95% CI 0.71-1.37, P value 0.93) and a lower risk of all-cause mortality (0.34% vs.
0.41%, RR 0.82, 95% CI 0.77-0.87, P value < 0.0001) (Appendix J).
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Ontario residents who were prescribed a new outpatient oral macrolide antibiotic
(azithromycin, clarithromycin or erythromycin) or non-macrolide antibiotic
(amoxicillin, cefuroxime or levofloxacin) between April 1, 2002 and March 1, 2013
(n = 1,726,846)

Patients excluded from study (n = 405,355)
Patients who died on or before the index date: 893
Patients <66 years on index date: 95,425
Prescriptions for any antibiotic in the 180 days
prior to the index date or evidence of two
different drug classes on the index date: 230,404
Discharged from a hospital in the two days prior
to the index date: 24,660
Atypical daily dose of study antibiotic: 53,973

Macrolide and non-macrolide antibiotic users following exclusions (n = 1,321,491)

Macrolide antibiotic users
(n = 616,359)

Non-macrolide antibiotic users
(n = 705,132)

Propensity score matching

Unmatched (n = 314,267)
Macrolides: 112,747
Non-macrolides: 201,520

Macrolide antibiotic users
(n = 503,612)

Figure 1. Flow diagram of cohort selection

Non-macrolide antibiotic users
(n = 503,612)

Table 2. Baseline characteristics of macrolide antibiotic (azithromycin, clarithromycin or erythromycin) users and non-macrolide
antibiotic (amoxicillin, cefuroxime or levofloxacin) users pre- and post-matcha

Variable
Demographics
Age, mean (SD), years
Women
Income quintilec
1 (low)
2
3 (middle)
4
5 (high)
Year of cohort entry
2002
2003
2004
2005
2006
2007
2008
2009
2010
2011

Macrolide
(n = 616,359)

Unmatched
Non-Macrolide
(n = 705,132)

Macrolide
(n = 503,612)

Matched
Non-Macrolide
(n = 503,612)

Standardized
Differenceb

Standardized
Differenceb

73.7 (7.1)
359,895 (58.4)

74.1 (7.3)
389,520 (55.2)

6%
6%

73.9 (7.2)
288,515 (57.3)

74.0 (7.2)
288,473 (57.3)

2%
0%

120,433 (19.5)
128,791 (20.9)
121,353 (19.7)
120,224 (19.5)
123,398 (20.0)

135,873 (19.3)
147,680 (20.9)
139,156 (19.7)
138,126 (19.6)
141,829 (20.1)

1%
0%
0%
0%
0%

99,340 (19.7)
106,101 (21.1)
101,012 (20.1)
97,895 (19.4)
99,264 (19.7)

100,535 (20.0)
106,738 (21.2)
101,455 (20.1)
97,247 (19.3)
97,637 (19.4)

1%
0%
0%
0%
1%

71,875 (11.7)
89,014 (14.4)
70,341 (11.4)
63,839 (10.4)
51,400 (8.3)
46,988 (7.6)
46,180 (7.5)
41,919 (6.8)
42,552 (6.9)
41,502 (6.7)

71,491 (10.1)
86,440 (12.3)
71,392 (10.1)
66,701 (9.5)
59,498 (8.4)
55,608 (7.9)
54,246 (7.7)
53,244 (7.6)
55,593 (7.9)
58,617 (8.3)

5%
6%
4%
3%
0%
1%
1%
3%
4%
6%

56,548 (11.2)
69,300 (13.8)
55,248 (11.0)
50,803 (10.1)
42,229 (8.4)
38,824 (7.7)
37,802 (7.5)
35,205 (7.0)
35,973 (7.1)
36,529 (7.3)

56,434 (11.2)
68,989 (13.7)
55,193 (11.0)
51,007 (10.1)
42,502 (8.4)
38,995 (7.7)
37,898 (7.5)
35,175 (7.0)
35,860 (7.1)
36,470 (7.2)

0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
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2012
2013
Rural residenced
Long-term care
LHINe
1
2
3
4
5
6
7
8
9
10
11
12
13
14
Prescribing physicianf
General practitioner
Internist
Nephrologist
Cardiologist
Other

41,276 (6.7)
9,473 (1.5)
87,490 (14.2)
20,921 (3.4)

60,475 (8.6)
11,827 (1.7)
89,820 (12.7)
37,020 (5.3)

7%
1%
4%
9%

37,075 (7.4)
8,076 (1.6)
68,952 (13.7)
20,538 (4.1)

37,011 (7.3)
8,078 (1.6)
67,861 (13.5)
23,129 (4.6)

0%
0%
1%
3%

35,679 (5.8)
48,731 (7.9)
30,062 (4.9)
75,103 (12.2)
28,553 (4.6)
43,184 (7.0)
49,886 (8.1)
74,884 (12.1)
71,866 (11.7)
30,641 (5.0)
60,098 (9.8)
23,560 (3.8)
31,464 (5.1)
12,029 (2.0)

36,429 (5.2)
56,169 (8.0)
32,784 (4.6)
95,783 (13.6)
36,298 (5.1)
52,734 (7.5)
61,560 (8.7)
88,508 (12.6)
88,861 (12.6)
32,286 (4.6)
58,581 (8.3)
24,074 (3.4)
30,400 (4.3)
9,981 (1.4)

3%
0%
1%
4%
2%
2%
2%
1%
3%
2%
5%
2%
4%
4%

29,201 (5.8)
39,542 (7.9)
24,531 (4.9)
61,236 (12.2)
23,584 (4.7)
35,609 (7.1)
40,894 (8.1)
61,529 (12.2)
58,702 (11.7)
24,907 (4.9)
49,208 (9.8)
18,914 (3.8)
25,408 (5.0)
9,847 (2.0)

27,684 (5.5)
40,003 (7.9)
22,812 (4.5)
68,781 (13.7)
26,199 (5.2)
36,197 (7.2)
43,485 (8.6)
61,848 (12.3)
64,162 (12.7)
22,293 (4.4)
41,608 (8.3)
17,158 (3.4)
23,275 (4.6)
7,627 (1.5)

1%
0%
2%
4%
2%
0%
2%
0%
3%
2%
5%
2%
2%
3%

474,660 (77.0)
2,797 (0.5)
802 (0.1)
856 (0.1)
37,133 (6.0%)

398,920 (56.6)
2,967 (0.4)
788 (0.1)
1,146 (0.2)
38,396 (5.4)

44%
1%
1%
1%
2%

367,302 (72.9)
2,461 (0.5)
749 (0.1)
813 (0.2)
32,194 (6.4)

368,847 (73.2)
2,611 (0.5)
626 (0.1)
909 (0.2)
34,646 (6.9)

1%
0%
1%
0%
2%
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Comorbiditiesg
Dementia
Schizophrenia or other
psychotic disorders
Bipolar disorder
Unipolar depression
and/or anxiety disorder
Haemorrhagic stroke
Ischemic stroke
TIA
Chronic liver disease
Chronic kidney diseaseh
Congestive heart failure
Coronary artery diseasei
Angina
Peripheral vascular
disease
Parkinson's disease
Chronic lung disease
Atrial fibrillation/flutter
Cancerj
Alcoholism
Seizure
Acute kidney injury
Acute myocardial
infarction
Pacemaker

46,958 (7.6)

68,671 (9.7)

8%

42,887 (8.5)

45,532 (9.0)

2%

12,614 (2.0)

17,771 (2.5)

3%

11,363 (2.3)

11,985 (2.4)

1%

9,964 (1.6)

12,986 (1.8)

2%

8,645 (1.7)

8,764 (1.7)

0%

46,254 (7.5)

53,089 (7.5)

0%

38,397 (7.6)

38,481 (7.6)

0%

1,056 (0.2)
6,544 (1.1)
2,545 (0.4)
19,210 (3.1)
27,800 (4.5)
61,351 (10.0)
158,521 (25.7)
117,261 (19.0)

1,556 (0.2)
9,804 (1.4)
3,475 (0.5)
23,094 (3.3)
36,539 (5.2)
77,802 (11.0)
190,688 (27.0)
135,415 (19.2)

1%
3%
1%
1%
3%
4%
3%
0%

957 (0.2)
6,005 (1.2)
2,263 (0.4)
16,167 (3.2)
25,543 (5.1)
56,214 (11.2)
138,038 (27.4)
99,400 (19.7)

990 (0.2)
6,366 (1.3)
2,363 (0.5)
16,299 (3.2)
25,543 (5.1)
56,214 (11.2)
138,038 (27.4)
99,463 (19.7)

0%
1%
0%
0%
0%
0%
0%
0%

8,365 (1.4)

10,267 (1.5)

1%

7,422 (1.5)

7,537 (1.5)

0%

8,858 (1.4)
177,653 (28.8)
25,513 (4.1)
76,143 (12.4)
3,578 (0.6)
3,058 (0.5)
6,238 (1.0)

13,096 (1.9)
167,962 (23.8)
39,678 (5.6)
86,596 (12.3)
4,757 (0.7)
4,290 (0.6)
9,090 (1.3)

3%
11%
7%
0%
1%
2%
3%

7,995 (1.6)
138,346 (27.5)
23,970 (4.8)
62,477 (12.4)
3,187 (0.6)
2,772 (0.6)
5,849 (1.2)

8,289 (1.6)
136,245 (27.1)
25,574 (5.1)
62,302 (12.4)
3,263 (0.6)
2,936 (0.6)
6,079 (1.2)

0%
1%
1%
0%
0%
0%
0%

18,673 (3.0)

23,811 (3.4)

2%

16,863 (3.3)

16,947 (3.4)

0%

23,606 (3.8)

31,405 (4.5)

3%

21,185 (4.2)

21,497 (4.3)

0%
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Hospitalization with
2,607 (0.4)
3,358 (0.5)
hyperkalemia
Hypotension
6,289 (1.0)
8,542 (1.2)
Prostatic hyperplasia
72,621 (11.8)
90,528 (12.8)
Prostatitis
28,193 (4.6)
33,028 (4.7)
Acute urinary retention
7,970 (1.3)
10,869 (1.5)
DVT/PE
942 (0.2)
1,611 (0.2)
k
Charlson comorbidity index
0
394,182 (64.0)
441,541 (62.6)
1
151,182 (24.5)
173,421 (24.6)
2
36,695 (6.0)
44,093 (6.3)
≥3
34,300 (5.6)
46,077 (6.5)
Johns Hopkins Aggregated Diagnosis Groups
0
14,708 (2.4)
18,706 (2.7)
1-2
107,191 (17.4)
129,336 (18.3)
3-5
256,541 (41.6)
289,615 (41.1)
≥6
237,919 (38.6)
267,475 (37.9)
l
Medication use
Antiarrhythmic
8,265 (1.3)
13,318 (1.9)
Antipsychotic
15,803 (2.6)
24,798 (3.5)
Proton pump inhibitor
113,986 (18.5)
127,557 (18.1)
Antiemetic
3,353 (0.5)
4,417 (0.6)
Lithium
1,230 (0.2)
1,737 (0.2)
Antilipemic
221,688 (36.0)
272,129 (38.6)
Antihypertensive
378,579 (61.4)
441,513 (62.6)

1%

2,374 (0.5)

2,422 (0.5)

0%

2%
3%
1%
2%
2%

5,661 (1.1)
61,284 (12.2)
23,411 (4.6)
7,068 (1.4)
892 (0.2)

5,838 (1.2)
61,487 (12.2)
23,426 (4.7)
7,248 (1.4)
1,005 (0.2)

0%
0%
0%
0%
1%

3%
0%
1%
4%

396,258 (78.7)
44,718 (8.9)
31,456 (6.2)
31,180 (6.2)

394,517 (78.3)
45,227 (9.0)
31,689 (6.3)
32,179 (6.4)

1%
0%
0%
1%

2%
2%
1%
1%

12,004 (2.4)
87,530 (17.4)
207,832 (41.3)
196,246 (39.0)

11,646 (2.3)
87,189 (17.3)
207,381 (41.2)
197,396 (39.2)

0%
0%
0%
0%

4%
6%
1%
1%
1%
5%
2%

7,897 (1.6)
14,803 (2.9)
94,018 (18.7)
2,971 (0.6)
1,071 (0.2)
188,554 (37.4)
315,012 (62.6)

8,306 (1.6)
15,909 (3.2)
94,081 (18.7)
3,137 (0.6)
1,079 (0.2)
189,507 (37.6)
316,392 (62.8)

1%
1%
0%
0%
0%
0%
1%
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Potassium sparing
diuretic
H2RA
Prokinetic
QT-prolonging
Antidiabetic
Acetylsalicylic acid
Anticoagulantm
Antiplatelet
Tricyclic
antidepressant
Opioid
Antimalarian
Antiviral
Antineoplastic
Benzodiazepine
NSAIDn
Cholinesterase
inhibitor
Anticonvulsant
ACE/ARB
Beta-adrenergic
antagonist
Calcium channel
blocker
Non-potassium
sparing diuretic

7,394 (1.2)

7,828 (1.1)

1%

5,943 (1.2)

5,882 (1.2)

0%

45,412 (7.4)
12,338 (2.0)
79,216 (12.9)
86,160 (14.0)
45,102 (7.3)
1,097 (0.2)
21,137 (3.4)

49,780 (7.1)
14,799 (2.1)
96,628 (13.7)
107,168 (15.2)
50,932 (7.2)
1,913 (0.3)
26,750 (3.8)

1%
1%
3%
3%
0%
2%
2%

37,562 (7.5)
10,793 (2.1)
68,376 (13.6)
74,116 (14.7)
38,140 (7.6)
1,053 (0.2)
18,705 (3.7)

38,034 (7.6)
10,792 (2.1)
68,376 (13.6)
75,326 (15.0)
38,469 (7.6)
1,116 (0.2)
18,835 (3.7)

0%
0%
0%
1%
0%
0%
0%

16,779 (2.7)

18,043 (2.6)

1%

13,898 (2.8)

13,639 (2.7)

0%

144 (0.0)
4,165 (0.7)
70 (0.0)
18,251 (3.0)
95,661 (15.5)
96,993 (15.7)

152 (0.0)
3,976 (0.6)
78 (0.0)
19,862 (2.8)
106,325 (15.1)
102,468 (14.5)

0%
1%
0%
1%
1%
3%

115 (0.0)
3,218 (0.6)
59 (0.0)
14,617 (2.9)
78,922 (15.7)
77,699 (15.4)

121 (0.0)
3,126 (0.6)
57 (0.0)
14,760 (2.9)
79,561 (15.8)
77,092 (15.3)

0%
0%
0%
0%
0%
0%

0 (0.0)

0 (0.0)

0%

-

-

-

12,039 (2.0)
244,089 (39.6)

17,052 (2.4)
286,273 (40.6)

3%
2%

10,861 (2.2)
203,598 (40.4)

11,419 (2.3)
204,220 (40.6)

1%
0%

143,479 (23.3)

175,820 (24.9)

4%

122,840 (24.4)

123,696 (24.6)

0%

137,188 (22.3)

162,728 (23.1)

2%

115,643 (23.0)

116,434 (23.1)

0%

140,191 (22.7)

164,702 (23.4)

1%

117,731 (23.4)

118,689 (23.6)

0%
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Statin
206,154 (33.4)
Antiparkinson drug
7,655 (1.2)
Digoxin
16,465 (2.7)
Overactive bladder
11,989 (1.9)
medication
Warfarin
28,511 (4.6)
Inhaler 26,454 (4.3)
acetylcholine
Inhaler - corticosteroid
38,465 (6.2)
Inhaler - beta-agonist
71,383 (11.6)
Smoking cessation aid
213 (0.0)
o
Health care use
GP/FP visits
588,000 (95.4)
Specialist consultations
Nephrologist consults
23,354 (3.8)
Cardiologist consults
192,925 (31.3)
Prior investigations and treatments
Carotid ultrasound
23,718 (3.8)
Cardiac catheterization
7,618 (1.2)
Coronary angiogram
8,845 (1.4)
Echocardiography
76,276 (12.4)
EEG
2,452 (0.4)
Holter monitoring
27,888 (4.5)
Cardiac stress test
59,803 (9.7)
Coronary
4,282 (0.7)
revascularization
ECG
270,574 (43.9)

253,885 (36.0)
11,610 (1.6)
27,748 (3.9)

5%
3%
7%

175,534 (34.9)
6,976 (1.4)
15,850 (3.1)

176,476 (35.0)
7,263 (1.4)
17,362 (3.4)

0%
0%
2%

15,337 (2.2)

2%

10,306 (2.0)

10,385 (2.1)

0%

52,322 (7.4)

12%

27,911 (5.5)

31,117 (6.2)

3%

26,784 (3.8)

3%

21,534 (4.3)

21,606 (4.3)

0%

32,138 (4.6)
61,638 (8.7)
220 (0.0)

7%
9%
0%

28,792 (5.7)
54,089 (10.7)
162 (0.0)

27,560 (5.5)
52,530 (10.4)
164 (0.0)

1%
1%
0%

671,789 (95.3)

1%

480,748 (95.5)

481,050 (95.5)

0%

31,104 (4.4)
233,623 (33.1)

3%
4%

20,866 (4.1)
163,132 (32.4)

21,237 (4.2)
164,185 (32.6)

0%
0%

27,395 (3.9)
10,102 (1.4)
11,493 (1.6)
95,002 (13.5)
3,074 (0.4)
35,025 (5.0)
68,956 (9.8)

0%
2%
2%
3%
1%
2%
0%

19,805 (3.9)
6,875 (1.4)
7,944 (1.6)
65,733 (13.1)
2,098 (0.4)
23,889 (4.7)
49,842 (9.9)

19,657 (3.9)
7,053 (1.4)
8,096 (1.6)
66,452 (13.2)
2,099 (0.4)
24,311 (4.8)
49,678 (9.9)

0%
0%
0%
0%
0%
0%
0%

5,866 (0.8)

2%

3,917 (0.8)

4,044 (0.8)

0%

319,725 (45.3)

3%

225,533 (44.8)

226,738 (45.0)

0%
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Colorectal cancer
screening
Cervical cancer
screening
PSA test
Mammography
Influenza vaccination
Bone mineral density
test
Hearing test
Cystoscopy
Transurethral
resection of the
prostate
CT of the head
CT of other areas
Chest x-ray
Pulmonary function
test
At-home physician
service
Urinalysis
Sputum

120,943 (19.6)

135,540 (19.2)

1%

96,970 (19.3)

96,028 (19.1)

0%

50,974 (8.3)

52,085 (7.4)

3%

39,122 (7.8)

38,535 (7.7)

0%

11,272 (1.8)
62,602 (10.2)
330,636 (53.6)

16,987 (2.4)
62,137 (8.8)
372,220 (52.8)

4%
5%
2%

10,216 (2.0)
48,148 (9.6)
269,517 (53.5)

10,024 (2.0)
47,222 (9.4)
269,306 (53.5)

0%
1%
0%

78,822 (12.8)

82,424 (11.7)

3%

61,728 (12.3)

60,823 (12.1)

1%

28,892 (4.7)
16,682 (2.7)

32,190 (4.6)
21,408 (3.0)

1%
2%

23,566 (4.7)
14,405 (2.9)

23,393 (4.6)
14,577 (2.9)

0%
0%

1,314 (0.2)

1,869 (0.3)

1%

1,169 (0.2)

1,211 (0.2)

0%

36,303 (5.9)
53,665 (8.7)
25,312 (4.1)

47,676 (6.8)
63,780 (9.0)
22,786 (3.2)

4%
1%
5%

31,556 (6.3)
45,195 (9.0)
19,484 (3.9)

32,637 (6.5)
45,595 (9.1)
19,263 (3.8)

1%
0%
0%

50,909 (8.3)

51,816 (7.3)

3%

40,495 (8.0)

40,142 (8.0)

0%

16,262 (2.6)

19,799 (2.8)

1%

14,109 (2.8)

14,329 (2.8)

0%

9,521 (1.5)
483 (0.1)

34,249 (4.9)
399 (0.1)

19%
1%

9,520 (1.9)
367 (0.1)

9,786 (1.9)
356 (0.1)

0%
0%
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Kidney functionp
Baseline SCr
concentration, median
(IQR), μmol/L
eGFR, median (IQR),
mL/min/1.73 m2q
eGFR
≥ 60 mL/min/1.73 m2
45-59 mL/min/1.73 m2
30-44 mL/min/1.73 m2
15-29 mL/min/1.73 m2
< 15 mL/min/1.73 m2
Urine dipstick proteinr
Negative (≤ 0.3 g/L)
0.3 g/L - 1.0 g/L
1.0 g/L - 3.0 g/L
≥ 3.0 g/L

78 (66-93)

79 (67-94)

4%

79 (67-93)

78 (66-93)

1%

74 (61-86)

74 (61-86)

2%

74 (61-86)

74 (61-86)

1%

81,332 (13.2)
16,125 (2.6)
6,352 (1.0)
1,735 (0.3)
226 (0.0)

95,913 (13.6)
19,597 (2.8)
8,217 (1.2)
2,478 (0.4)
310 (0.0)

1%
1%
1%
1%
0%

66,755 (13.3)
13,793 (2.7)
5,630 (1.1)
1,581 (0.3)
217 (0.0)

66,942 (13.3)
13,534 (2.7)
5,637 (1.1)
1,661 (0.3)
202 (0.0)

0%
0%
0%
0%
0%

612 (0.1)
8,734 (1.4)
6,985 (1.1)
6,250 (1.0)

803 (0.1)
10,935 (1.6)
8,933 (1.3)
8,444 (1.2)

0%
1%
1%
2%

533 (0.1)
7,362 (1.5)
5,926 (1.2)
5,517 (1.1)

508 (0.1)
7,372 (1.5)
6,148 (1.2)
5,711 (1.1)

0%
0%
0%
0%

Abbreviations: ACE = angiotensin-converting enzyme, ARB = angiotensin II receptor blocker, CKD = chronic kidney disease, CKD-EPI =
Chronic Kidney Disease Epidemiology Collaboration, CT = computed tomography, DVT/PE = deep vein thrombosis/pulmonary embolism,
ECG = electrocardiography, EEG = electroencephalography, eGFR = estimated glomerular filtration rate, GP/FP = general practitioner/family
practitioner, H2RA = histamine H2-receptor antagonist, IQR = interquartile range, LHIN = Local Health Integration Network, NSAID = nonsteroidal anti-inflammatory drug, PSA = prostate-specific antigen, SCr = serum creatinine, SD = standard deviation, TIA = transient ischemic
attack
a
Data are presented as the number (percentage) of patients, unless otherwise reported.
b
Standardized differences are less sensitive to sample size than traditional hypothesis tests. They provide a measure of the difference between
groups divided by the pooled standard deviation; a value greater than 10% (0.1) is interpreted as a meaningful difference between the groups (71).
c
Income was categorized into fifths of average neighborhood income on the index date. Income was not available for 2,160 (0.4%) macrolide
antibiotic users and 2,468 (0.4%) non-macrolide antibiotic users in the unmatched cohort. Missing values in the unmatched cohort were
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re-classified into income quintile 3 during matching.
d
Rural residence was defined as a population < 10,000 people. Residential information was not available for 647 (0.1%) macrolide antibiotic users
and 708 (0.1%) non-macrolide antibiotic users in the unmatched cohort. Missing values in the unmatched cohort were re-classified into the "No"
category during matching.
e
LHIN refers to health authorities responsible for regional administration of public healthcare services in Ontario. LHIN was not available for 619
(0.1%) macrolide antibiotic users and 684 (0.1%) non-macrolide antibiotic users in the unmatched cohort and 500 (0.1%) macrolide users and 480
(0.1%) non-macrolide antibiotic users in the matched cohort.
f
Prescriber information was not available for 100,111 (16.2%) macrolide antibiotic users and 262,915 (37.3%) non-macrolide antibiotic users in
the unmatched cohort and 100,093 (19.9%) macrolide antibiotic users and 95,973 (19.1%) non-macrolide antibiotic users in the matched cohort.
g
Comorbid conditions in the five years preceding the index date were considered.
h
We identified CKD using an algorithm of hospital diagnostic diagnosis codes validated for older adults in our region (83). The presence of codes
in this algorithm is associated with a median eGFR of 38 mL/min/1.73 m2 (IQR 27 to 52 mL/min/1.73 m2), whereas an absence of codes is
associated with a median eGFR of 69 mL/min/1.73 m2 (IQR 56 to 82 mL/min/1.73 m2).
i
Coronary artery disease included receipt of coronary artery bypass graft surgery and percutaneous coronary intervention.
j
Major cancers included esophagus, lung, bowel, liver, pancreas, breast, male/female reproductive organs, as well as leukemias and lymphomas.
k
Charlson comorbidity index (84,85) was calculated using five years of hospitalization data. "No hospitalizations" received a score of 0.
l
Baseline medication use in the 120 days preceding the index date was considered.
m
Excludes warfarin.
n
Excludes acetylsalicylic acid.
o
Chest x-ray, urinalysis and sputum were assessed in the seven days preceding the index date. All other health care use was assessed in the one
year preceding the index date.
p
Baseline SCr measurements were taken in routine care a median of 131 days (IQR 59 to 227 days) and 126 days (IQR 57 to 224 days) prior to the
index date for macrolide antibiotic users and non-macrolide antibiotic users, respectively, in the unmatched cohort and 129 days (IQR 59 to 225
days) and 127 days (IQR 58 to 224 days) prior to the index date for macrolide antibiotic users and non-macrolide antibiotic users, respectively, in
the matched cohort.
q
eGFR was calculated using the CKD-EPI equation (86): 141 × min([serum creatinine concentration in μmol/L/88.4]/ĸ, 1)α × max([serum
creatinine concentration in μmol/L/88.4]/ĸ, 1)-1.209 × 0.993Age × 1.018 [if female] × 1.159 [if African-American]; ĸ = 0.7 if female and 0.9 if male;
α = -0.329 if female and -0.411 if male; min = the minimum of serum creatinine concentration/ĸ or 1; max = the maximum of serum creatinine
concentration/ĸ or 1. Information on race was not available in our data sources and all patients were assumed not to be of African-Canadian race;
African-Canadians represented less than 5% of the population of Ontario in 2006 (87).
r
Urine dipstick protein measurements were available for 22,581 (3.7%) macrolide antibiotic users and 29,115 (4.1%) non-macrolide antibiotic
users in the unmatched cohort and 19,338 (3.8%) macrolide antibiotic users and 19,739 (3.9%) non-macrolide antibiotic users in the matched
cohort.
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Table 3. 30-day risk for hospital encounter with ventricular arrhythmia and all-cause
mortality in matched cohort of patients prescribed macrolide antibiotics compared to
referent non-macrolide antibiotics

Outcome
Ventricular
arrhythmiaa
All-cause
mortality

Events, n (%)
Macrolide
Non-Macrolide
(n = 503,612)
(n = 503,612)

Relative Risk
(95% CI)

P value

134 (0.03)

126 (0.03)

1.06 (0.83-1.36)

0.62

3,144 (0.62)

3,833 (0.76)

0.82 (0.78-0.86)

< 0.0001

Abbreviations: CI = confidence interval
a
Based on hospital presentation (emergency room or hospitalization) assessed by
hospital diagnosis codes. This method of assessment underestimated the true number of
events as ventricular arrhythmias frequently go undetected in routine healthcare
(because they often occur outside hospital settings, in unmonitored patients in hospital
or in a setting of multi-organ medical illness where recorded codes describe other
illnesses besides the ventricular arrhythmia).

No. events / No. at risk
Macrolide

% with event

Non-macrolide

Macrolide

Non-macrolide

Relative risk

Interaction test

(95% confidence interval)

(P value)

Chronic kidney disease
Yes

20 / 25,543

25 / 25,543

0.08

0.10

0.80 (0.44 to 1.44)

No

114 / 478,069

101 / 478,069

0.02

0.02

1.13 (0.86 to 1.48)

0.30
Congestive heart failure
Yes

60 / 56,214

48 / 56,214

0.11

0.09

1.25 (0.86 to 1.83)

No

74 / 447,398

78 / 447,398

0.02

0.02

0.95 (0.69 to 1.30)

0.28
Coronary artery disease
Yes

86 / 138,038

79 / 138,038

0.06

0.06

1.09 (0.80 to 1.48)

No

48 / 365,574

47 / 365,574

0.01

0.01

1.02 (0.68 to 1.53)

0.80
Taking QT-prolonging drug
Yes

29 / 68,376

23 / 68,376

0.04

0.03

1.26 (0.73 to 2.18)

No

105 / 435,236

103 / 435,236

0.02

0.02

1.02 (0.78 to 1.34)

0.50

0

Risk lower with
macrolide use

1

2

Risk higher with
macrolide use

Figure 2. The association between macrolide antibiotic prescription (azithromycin, clarithromycin or erythromycin) and 30-day
hospital encounter with ventricular arrhythmiaa examined in subgroups defined by CKD, CHF, CAD and QT-prolonging drug use
Abbreviations: CAD = coronary artery disease, CHF = congestive heart failure, CKD = chronic kidney disease
Data marker size is proportional to the inverse of the source variance.
a
Based on hospital presentation (emergency room or hospitalization) assessed by hospital diagnosis codes. This method of assessment
underestimated the true number of events as ventricular arrhythmias frequently go undetected in routine healthcare (because they often
occur outside hospital settings, in unmonitored patients in hospital or in a setting of multi-organ medical illness where recorded codes
describe other illnesses besides the ventricular arrhythmia).
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No. events / No. at risk
Macrolide

% with event

Non-macrolide

Macrolide

Non-macrolide

Relative risk

Interaction test

(95% confidence interval)

(P value)

Chronic kidney disease
Yes

402 / 25,543

441 / 25,543

1.57

1.73

0.91 (0.79 to 1.04)

No

2,742 / 478,069

3,392 / 478,069

0.57

0.71

0.81 (0.77 to 0.85)

0.11
Congestive heart failure
Yes

987 / 56,214

1,184 / 56,214

1.76

2.11

0.83 (0.76 to 0.90)

No

2,157 / 447,398

2,649 / 447,398

0.48

0.59

0.81 (0.77 to 0.86)

0.67
Coronary artery disease
Yes

1,228 / 138,038

1,452 / 138,038

0.89

1.05

0.84 (0.78 to 0.91)

No

1,916 / 365,574

2,381 / 365,574

0.52

0.65

0.80 (0.75 to 0.85)

0.31
Taking QT-prolonging drug
Yes

852 / 68,376

1,095 / 68,376

1.25

1.60

0.77 (0.71 to 0.85)

No

2,292 / 435,236

2,738 / 435,236

0.53

0.63

0.84 (0.79 to 0.88)

0.16

0.5

Risk lower with
macrolide use

1

1.5

Risk higher with
macrolide use

Figure 3. The association between macrolide antibiotic prescription (azithromycin, clarithromycin or erythromycin) and 30-day
all-cause mortality examined in subgroups defined by CKD, CHF, CAD and QT-prolonging drug use
Abbreviations: CAD = coronary artery disease, CHF = congestive heart failure, CKD = chronic kidney disease
Data marker size is proportional to the inverse of the source variance.
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Chapter 6

6

Discussion

In this population-based cohort study, we observed that new use of a macrolide antibiotic
compared to non-macrolide antibiotics was associated with a similar 30-day risk of
ventricular arrhythmia (0.03% vs. 0.03%) and a slightly lower risk of all-cause mortality
(0.62% vs. 0.76%).

6.1 Summary and interpretation of study results
The studies included in our literature review show inconsistent findings. Although a
plausible explanation for these observed differences may be variation in the average age,
sex and baseline comorbidity of the studied populations, some publications warrant
further attention.
Of particular interest is the comparison of our findings with those of Ray et al. who
observed a higher 5-day risk of cardiovascular death (HR 2.49, 95% CI 1.38-4.50) and
death from any cause (HR 2.02, 95% CI 1.24-3.30) among patients taking azithromycin
compared with those taking amoxicillin (8). Although the authors matched azithromycin
use to antibiotic non-use, no matching was done for those prescribed amoxicillin.
Compared with the azithromycin group, patients receiving amoxicillin seemed healthier
overall, with lower percentages of baseline medication use (with the exception of digoxin
and insulin), lower prevalence of comorbidities and fewer hospitalizations and
emergency department visits. Accordingly, fewer deaths could have occurred among
those receiving amoxicillin if they were less prone to events than the macrolide antibiotic
group.
In this same study, the authors reported the greatest risk of cardiovascular death in
patients with the highest baseline risk of cardiovascular disease. Additionally, Schembri
et al. reported an increased risk of cardiovascular events with prolonged courses of
clarithromycin (> 7 days), especially in patients with pre-existing coronary artery disease
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(18). For these reasons, we explored congestive heart failure and coronary artery disease
as subgroups in our study. We found that these variables did not significantly alter the
association between macrolide antibiotic use and our outcomes. Nonetheless, these
findings should be interpreted with caution and physicians should always consider a
patient’s baseline risk for adverse events before prescribing macrolides or other
antibiotics. Patients at particular risk include those with existing QT interval
prolongation, a history of torsades de pointes, hypokalemia, hypomagnesemia, significant
bradycardia, bradyarrhythmias or use of certain antiarrhythmic drugs (88–90). To
minimize risk, others advocate for ECG to monitor the QT interval before and after
initiating therapy (91).
A plausible explanation for the observed reduction in 30-day all-cause mortality with
macrolide antibiotic use may be their immunomodulatory effects (92). These effects are
believed to be mediated by several properties of macrolide antibiotics that have been
observed including decreases in pro-inflammatory cytokines (TNF-α, IL-1, IL-6, IL-8
and IFN-γ), increases in anti-inflammatory cytokines and decreases in neutrophil
chemotaxis, leukocyte adhesion, and oxidative metabolism (93). However, because the
absolute magnitude of this effect was small, this finding should be interpreted with
caution.

6.2 Study strengths and limitations
Our study has several strengths. The use of Ontario’s healthcare databases with data on
universal prescription drug coverage in older adults provided us with a large
representative sample of patients who received the study antibiotics in routine care. This
allowed us to estimate the risks of uncommon but serious adverse events with good
precision and external validity. We assessed clinically important adverse events (hospital
encounter with ventricular arrhythmia and death), rather than relying on surrogate
outcomes such as a prolonged QT interval on an ECG, making these findings of
particular interest to clinicians and regulatory agencies. We used the non-macrolide
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antibiotics amoxicillin, cefuroxime and levofloxacin as a referent group to reduce the
influence of confounding by indication.
Experimental studies provide the strongest evidence for whether or not an exposure has
an effect on the risk of a disease (94). However, clinical trials are costly and the relatively
small number of patients enrolled in the trials makes the estimation of risk for relatively
rare adverse drug events difficult (95). Large observational studies can complement the
findings of clinical trials by enabling the investigation of uncommon but important
adverse drug events with adequate statistical power. Moreover, such observational studies
can include vulnerable groups of patients who may be excluded from clinical trials and
better reflect what occurs in routine clinical settings where treatments and monitoring are
less regulated than in clinical trials (96,97)
Our study has some limitations. Prospective data collection with independent outcome
adjudication would be a preferred methodology to assess risk. In this study, we analyzed
retrospective data using administrative diagnosis codes assigned from physician records,
and cardiac rhythm tracings were not available in our data sources. The diagnosis codes
we used for a hospital encounter with ventricular arrhythmia have a good PPV but limited
sensitivity. However, we have no reason to suspect any systematic difference in
diagnostic recording by antibiotic type, suggesting that our relative measures of risk are
robust. As with all observational studies, residual confounding can never be eliminated;
however, we used a statistical technique to ensure our comparison groups were similar on
106 measured baseline characteristics. Our findings might not generalize well to other
regions if Ontario physicians deliberately avoided prescribing macrolide antibiotics to
patients at highest risk of ventricular arrhythmia (such as those with baseline QT
prolongation), or discontinued macrolide antibiotics when the QT interval was prolonged
in a follow-up ECG. However, our impression is that Ontario physicians rarely take
ventricular arrhythmia risk into account when deciding to prescribe a macrolide.
Although shorter follow-up periods were used in prior studies (8–10,12,17,18,37), we
consider the 30-day follow-up used in our study to be clinically relevant. We did,
however, repeat our analyses within 14 days of macrolide antibiotic prescription and
found similar results.
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6.3 Study implications
This study was prompted by Health Canada and U.S. FDA warnings about a higher risk
of QT interval prolongation and subsequent ventricular arrhythmia among patients taking
azithromycin (5,6). Though caution should be exercised when prescribing macrolide
antibiotics to high-risk patients where drug clearance or electrical activity of the heart is
impaired and outcomes less predictable, our study findings and examination of the
current literature suggest that the risk of ventricular arrhythmia and death from macrolide
antibiotic use may be overstated. A careful re-examination and updating of drug
prescribing references (44,57–59) and warnings from regulatory agencies appears
warranted. The findings from this study are reassuring for health care providers who
prescribe macrolide antibiotics to a wide range of patients in routine care.
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Appendices
Appendix A. Modified Downs and Black checklist for the assessment of the
methodological quality of both randomized and non-randomized studies (36)
Item Criteria
Reporting
Is the hypothesis/aim/objective of the study clearly
1
described?
Are the main outcomes to be measured clearly described in
the Introduction or Methods section? If the main outcomes
2
are first mentioned in the Results section, the question
should be answered no.
Are the characteristics of the patients included in the study
clearly described? In cohort studies and trials, inclusion
3
and/or exclusion criteria should be given. In case-control
studies, a case-definition and the source for controls should
be given.
Are the interventions of interest clearly described?
4
Treatments and placebo (where relevant) that are to be
compared should be clearly described.
Are the distributions of principal confounders in each
5
group of subjects to be compared clearly described? A list
of principal confounders is provided.
Are the main findings of the study clearly described?
Simple outcome data (including denominators and
numerators) should be reported for all major findings so
6
that the reader can check the major analyses and
conclusions. (This question does not cover statistical tests
which are considered below).
Does the study provide estimates of the random variability
in the data for the main outcomes? In non-normally
distributed data the interquartile range of results should be
reported. In normally distributed data the standard error,
7
standard deviation or confidence intervals should be
reported. If the distribution of the data is not described, it
must be assumed that the estimates used were appropriate
and the question should be answered yes.
Have all important adverse events that may be a
consequence of the intervention been reported? This
should be answered yes if the study demonstrates that there
8
was a comprehensive attempt to measure adverse events.
(A list of possible adverse events is provided).

Possible Answers
Yes = 1
No = 0
Yes = 1
No = 0

Yes = 1
No = 0

Yes = 1
No = 0
Yes = 2
Partially = 1
No = 0
Yes = 1
No = 0

Yes = 1
No = 0

Yes = 1
No = 0
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Have the characteristics of patients lost to follow-up been
described? This should be answered yes where there were
no losses to follow-up or where losses to follow-up were so
9
small that findings would be unaffected by their inclusion.
This should be answered no where a study does not report
the number of patients lost to follow-up.
Have actual probability values been reported (e.g. 0.035
10 rather than <0.05) for the main outcomes except where the
probability value is less than 0.001?
External validity
Were the subjects asked to participate in the study
representative of the entire population from which they
were recruited? The study must identify the source
population for patients and describe how the patients were
selected. Patients would be representative if they
comprised the entire source population, an unselected
11
sample of consecutive patients, or a random sample.
Random sampling is only feasible where a list of all
members of the relevant population exists. Where a study
does not report the proportion of the source population
from which the patients are derived, the question should be
answered as unable to determine.
Were those subjects who were prepared to participate
representative of the entire population from which they
were recruited? The proportion of those asked who agreed
12 should be stated. Validation that the sample was
representative would include demonstrating that the
distribution of the main confounding factors was the same
in the study sample and the source population.
Were the staff, places, and facilities where the patients
were treated, representative of the treatment the majority
of patients receive? For the question to be answered yes
the study should demonstrate that the intervention was
13 representative of that in use in the source population. The
question should be answered no if, for example, the
intervention was undertaken in a specialist centre
unrepresentative of the hospitals most of the source
population would attend.
Internal validity - bias
Was an attempt made to blind study subjects to the
intervention they have received? For studies where the
14
patients would have no way of knowing which intervention
they received, this should be answered yes.

Yes = 1
No = 0

Yes = 1
No = 0

Yes = 1
No = 0
Unable to
determine = 0

Yes = 1
No = 0
Unable to
determine = 0

Yes = 1
No = 0
Unable to
determine = 0

Yes = 1
No = 0
Unable to
determine = 0
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15

Was an attempt made to blind those measuring the main
outcomes of the intervention?

If any of the results of the study were based on “data
dredging”, was this made clear? Any analyses that had not
16 been planned at the outset of the study should be clearly
indicated. If no retrospective unplanned subgroup analyses
were reported, then answer yes.
In trials and cohort studies, do the analyses adjust for
different lengths of follow-up of patients, or in case-control
studies, is the time period between the intervention and
outcome the same for cases and controls? Where follow17 up was the same for all study patients the answer should be
yes. If different lengths of follow-up were adjusted for by,
for example, survival analysis the answer should be yes.
Studies where differences in follow-up are ignored should
be answered no.
Were the statistical tests used to assess the main outcomes
appropriate? The statistical techniques used must be
appropriate to the data. For example nonparametric
methods should be used for small sample sizes. Where
18 little statistical analysis has been undertaken but where
there is no evidence of bias, the question should be
answered yes. If the distribution of the data (normal or not)
is not described it must be assumed that the estimates used
were appropriate and the question should be answered yes.
Was compliance with the intervention/s reliable? Where
there was non-compliance with the allocated treatment or
where there was contamination of one group, the question
19
should be answered no. For studies where the effect of any
misclassification was likely to bias any association to the
null, the question should be answered yes.
Were the main outcome measures used accurate (valid and
reliable)? For studies where the outcome measures are
clearly described, the question should be answered yes. For
20
studies which refer to other work or that demonstrates the
outcome measures are accurate, the question should be
answered as yes.
Internal validity - confounding (selection bias)
Were the patients in different intervention groups (trials
and cohort studies) or were the cases and controls (casecontrol studies) recruited from the same population? For
21
example, patients for all comparison groups should be
selected from the same hospital. The question should be
answered unable to determine for cohort and case-control

Yes = 1
No = 0
Unable to
determine = 0
Yes = 1
No = 0
Unable to
determine = 0
Yes = 1
No = 0
Unable to
determine = 0

Yes = 1
No = 0
Unable to
determine = 0

Yes = 1
No = 0
Unable to
determine = 0
Yes = 1
No = 0
Unable to
determine = 0

Yes = 1
No = 0
Unable to
determine = 0
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22

23

24

25

26

studies where there is no information concerning the
source of patients included in the study.
Were study subjects in different intervention groups (trials
and cohort studies) or were the cases and controls (casecontrol studies) recruited over the same period of time?
For a study which does not specify the time period over
which patients were recruited, the question should be
answered as unable to determine.
Were study subjects randomized to intervention groups?
Studies which state that subjects were randomized should
be answered yes except where method of randomization
would not ensure random allocation. For example alternate
allocation would score no because it is predictable.
Was the randomized intervention assignment concealed
from both patients and health care staff until recruitment
was complete and irrevocable? All non-randomized
studies should be answered no. If assignment was
concealed from patients but not from staff, it should be
answered no.
Was there adequate adjustment for confounding in the
analyses from which the main findings were drawn? This
question should be answered no for trials if: the main
conclusions of the study were based on analyses of
treatment rather than intention to treat; the distribution of
known confounders in the different treatment groups was
not described; or the distribution of known confounders
differed between the treatment groups but was not taken
into account in the analyses. In non-randomized studies if
the effect of the main confounders was not investigated or
confounding was demonstrated but no adjustment was
made in the final analyses the question should be answered
as no.
Were losses of patients to follow-up taken into account? If
the numbers of patients lost to follow-up are not reported,
the question should be answered as unable to determine. If
the proportion lost to follow-up was too small to affect the
main findings, the question should be answered yes.

Yes = 1
No = 0
Unable to
determine = 0
Yes = 1
No = 0
Unable to
determine = 0
Yes = 1
No = 0
Unable to
determine = 0
Yes = 1
No = 0
Unable to
determine = 0

Yes = 1
No = 0
Unable to
determine = 0

Power
27a

a

Did the study have sufficient power to detect a clinically
important effect where the probability value for a
difference being due to chance is less than 5%? Sample
sizes have been calculated to detect a difference of x% and
y%.

Item has been modified.

Yes = 1
No = 0
Unable to
determine = 0
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Appendix B. Checklist of recommendations for reporting of observational studies using
the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE)
guidelines (40)

Title and
abstract

Item
No

Recommendation

1

(a) Indicate the study's design with
a commonly used term in the title
or the abstract
(b) Provide in the abstract an
informative and balanced
summary of what was done and
what was found

Reported
Abstract

Abstract

Introduction
Background/
rationale

2

Objectives

3

Explain the scientific background
and rationale for the investigation
being reported
State specific objectives, including
any prespecified hypotheses

Chapters 1, 2 & 3
Chapter 3

Methods
Study design

4

Setting

5

Participants

6

Variables

7

Data sources/
measurement

8

Present key elements of study
design early in the paper
Describe the setting, locations, and
relevant dates, including periods of
recruitment, exposure, follow-up,
and data collection
(a) Give the eligibility criteria, and
the sources and methods of
selection of participants. Describe
methods of follow-up
(b) For matched studies, give
matching criteria and number of
exposed and unexposed
Clearly define all outcomes,
exposures, predictors, potential
confounders, and effect modifiers.
Give diagnostic criteria, if
applicable
For each variable of interest, give
sources of data and details of
methods of assessment
(measurement). Describe
comparability of assessment

Chapter 4
Chapter 4

Chapter 4, Figure 1

Chapter 4, Figure 1
Chapter 4,
Appendices C, D,
E, F & G

Chapter 4,
Appendices C & D
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methods if there is more than one
group

Bias
Study size
Quantitative
variables

Statistical
methods

9

Describe any efforts to address
potential sources of bias

Chapters 4 & 6

10

Explain how the study size was
arrived at

Chapter 4; based on
availability of the
data

11

12

Explain how quantitative variables
were handled in the analyses. If
applicable, describe which
groupings were chosen and why
(a) Describe all statistical methods,
including those used to control for
confounding
(b) Describe any methods used to
examine subgroups and
interactions
(c) Explain how missing data were
addressed
(d) If applicable, explain how loss
to follow-up was addressed
(e) Describe any sensitivity
analyses

Chapter 4

Chapter 4
Chapter 4
Chapter 4
Not applicable
Chapter 4

Results

Participants

Descriptive data

13

14

(a) Report numbers of individuals
at each stage of study-e.g. numbers
potentially eligible, examined for
eligibility, confirmed eligible,
included in the study, completing
follow-up, and analyzed
(b) Give reasons for nonparticipation at each stage
(c) Consider use of a flow diagram
(a) Give characteristics of study
participants (e.g. demographic,
clinical, social) and information on
exposures and potential
confounders
(b) Indicate number of participants
with missing data for each variable
of interest
(c) Summarize follow-up time
(e.g. average and total amount)

Chapter 5, Figure 1

Chapter 5, Figure 1
Figure 1
Chapter 5, Table 2,
Appendix G
Chapter 5, Table 2,
Appendix I
Chapter 5
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Outcome data

15

Main results

16

Other analyses

17

Report numbers of outcome events
Chapter 5, Table 3
or summary measures over time
(a) Give unadjusted estimates and,
if applicable, confounder-adjusted
estimates and their precision (e.g.
Chapter 5, Table 2,
95% confidence interval). Make
Appendix G
clear which confounders were
adjusted for and why they were
included
(b) Report category boundaries
when continuous variables were
Not applicable
categorized
(c) If relevant, consider translating
estimates of relative risk into
Not applicable
absolute risk for a meaningful time
period
Report other analyses done-e.g.
Chapter 5, Figures 1
analyses of subgroups and
and 2, Appendices I
interactions, and sensitivity
&J
analyses

Discussion
Key results

18

Limitations

19

Interpretation

20

Generalizability

21

Summarize key results with
reference to study objectives
Discuss limitations of the study,
taking into account sources of
potential bias or imprecision.
Discuss both direction and
magnitude of any potential bias
Give a cautious overall
interpretation of results
considering objectives, limitations,
multiplicity of analyses, results
from similar studies, and other
relevant evidence
Discuss the generalizability
(external validity) of the study
results

Chapter 6

Chapter 6

Chapter 6

Chapter 6

Other information
Funding

22

Give the source of funding and the
role of the funders for the present
study and, if applicable, for the
original study on which the present
article is based

Acknowledgements
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Appendix C. Coding definitions for demographics and comorbid conditions
Variable
Demographics
Age
Sex
Socioeconomic status
(neighbourhood income
quintiles)
Location of residence Rural status
Long-term care
Prescribing physician /
LHINa
Comorbidities
Dementia

Database
RPDB
RPDB
Statistics
Canada
Statistics
Canada
ODB
RPDB

CIHI-DAD

OHIP
OMHRS
Schizophrenia or other
psychotic disorders

CIHI-DAD

OHIP
OMHRS

Bipolar disorder

Codes

CIHI-DAD
OHIP
OMHRS

LTC
LHIN

ICD-9: 2900, 2901, 2903, 2904, 2908,
2909, 2948, 2949, 3310-3312, 2941, 797
ICD-10: F00-F03, F051, F065, F066,
F068, F069, F09, G30, G31, R54
OHIP dx: 290, 331, 797
DSM-IV: 29040-29043, 29120, 29282,
29410, 29411, 29480, 78090
ICD-9: 2950-2959, 2970-2973, 2978-2981,
2983, 2984, 2988, 2989
ICD-10: F060, F062, F105, F107, F115,
F117, F125, F127, F135, F137, F145,
F147, F155, F157, F165, F167, F175,
F177, F185, F187, F195, F197, F200F206, F208, F209, F220, F228-F233,
F238, F239, F24, F250-F252, F258, F259,
F28, F29
OHIP dx: 291, 292, 295, 297, 298
OHIP fee: Q021
DSM-IV: 29130, 29150, 29211, 29212,
29381, 29382, 29510, 29520, 29530,
29540, 29560, 29570, 29590, 29710,
29730, 29880, 29890
ICD-9: 2960, 2961, 2964-2968
ICD-10: F300-F302, F308-F319
OHIP dx: 296
OHIP fee: Q020
DSM-IV: 29600-29606, 29640-29646,
29650-29656, 29660-29666, 29670, 29680,
29689
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Unipolar depression
and/or anxiety disorder

CIHI-DAD

OHIP
OMHRS

Haemorrhagic stroke

CIHI-DAD

Ischemic stroke

CIHI-DAD

Transient ischemic
attack
Chronic kidney disease

CIHI-DAD
CORR
CIHI-DAD

OHIP

CIHI-DAD
OHIP

CIHI-DAD
OHIP

CIHI-DAD

OHIP

ICD-9: 2962, 2963, 3000, 3002-3004,
3091, 311
ICD-10: F063, F064, F320-F323, F328F334, F338, F339, F341, F400-F402,
F408-F413, F418-F422, F428-F431
OHIP dx: 311
DSM-IV: 29189, 29284, 29289, 29383,
29384, 29620-29626, 29630-29636,
30000-30002, 30021-30023, 30029, 30030,
30040, 30113
ICD-9: 430, 431
ICD-10: I600-I607, I609, I61
ICD-9: 434, 436
ICD-10: H341, I630-I635, I638, I639
ICD-9: 4358, 4359
ICD-10: G45
Transplant
Treatment code: 171, 181
Transplanted organ: 10-12, 18, 19
ICD-9: V420, 99681
ICD-10: N165, T861, Z940
CCP: 6743, 675
CCI: 1PC85
OHIP fee: E762, E769, E771, G347, G348,
G408, G409, G412, S434, S435, Z631
Peritoneal dialysis
CCP: 6698
CCI: 1PZ21HPD4
OHIP fee: G330-G333, G861, G864,
H540, H740
Hemodialysis
CCP: 5195
CCI: 1PZ21HQBR, 1PZ21HQBS
OHIP fee: G082, G083, G085, G090G096, G294, G295, G323, G325, G326,
G333, G860, G862, G863, G865, G866,
H540, H740, R849
Chronic kidney disease
ICD-9: 2504, 4030, 4031, 4039-4041,
4049, 585, 586, 5888, 5889
ICD-10: E102, E112, E132, E142, I12, I13,
N08, N18, N19
OHIP dx: 403, 585
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Chronic liver disease

CIHI-DAD

OHIP
Congestive heart failure

CIHI-DAD

OHIP
Coronary artery disease
(minus angina)

CIHI-DAD

OHIP
Angina
Peripheral vascular
disease

CIHI-DAD
OHIP
CIHI-DAD

OHIP

Parkinson’s disease

CIHI-DAD

Chronic lung disease

OHIP
CIHI-DAD

ICD-9: 070, 2750, 2751, 4561, 4562, 571,
5722-5724, 5728, 573, 7824, 7891, 7895,
V026
ICD-10: B16-B19, B942, E830, E831, I85,
K70, K713-K715, K717, K721, K729,
K73, K74, K753, K754, K758, K759, K76,
K77, R160, R162, R17, R18, Z225
OHIP dx: 070, 571, 573
OHIP fee: Z551, Z554
ICD-9: 425, 428, 514, 5184
ICD-10: I255, I500, I501, I509, J81
CCP: 4961-4964
CCI: 1HP53, 1HP55, 1HZ53GRFR,
1HZ53LAFR, 1HZ53SYFR
OHIP dx: 428
OHIP fee: R701, R702, Z429
ICD-9: 410, 412, 414, 4292, 4295-4297
ICD-10: I21-I25, R931, T822, Z955, Z958,
Z959
CCP: 4801-4805, 481-483
CCI: 1IJ26, 1IJ27, 1IJ50, 1IJ54, 1IJ57,
1IJ76
OHIP dx: 410, 412
OHIP fee: E646, E651, E652, E654, E655,
G262, G298, R741-R743, Z434, Z448
ICD-9: 413
ICD-10: I20
OHIP dx: 413
ICD-9: 4402, 4408, 4409, 4439, 444, 5571
ICD-10: I700, I702, I708, I709, I731, I738,
I739, K551
CCP: 5014, 5016, 5018, 5028, 5038, 5125,
5129
CCI: 1KA50, 1KA76, 1KE76, 1KG26,
1KG50, 1KG57, 1KG76MI, 1KG87
OHIP fee: E626, E649, E672, R780, R783R787, R791, R794, R797, R804, R809,
R813-R815, R855, R856, R867, R875,
R936, R937, R860, R861, R933, R934
ICD-9: 332
ICD-10: F023, G20
OHIP dx: 332
ICD-9: 4168, 4169, 491-496, 500-505,
5064, 5069, 5081, 515-517, 5185, 5188,
5198, 5199
ICD-10: I272, I278, I279, J40-J45, J47,
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OHIP
Atrial fibrillation/flutter

CIHI-DAD

Cancer

CIHI-DAD

OHIP
Alcoholism

CIHI-DAD

Seizure

CIHI-DAD

Acute kidney injury

CIHI-DAD

Acute myocardial
infarction
Pacemaker

CIHI-DAD
CIHI-DAD

OHIP
Hyperkalemia

CIHI-DAD

Hypotension

CIHI-DAD

Prostatic hyperplasia

CIHI-DAD
OHIP

J60-J68, J701, J703, J704, J708, J709, J82,
J84, J92, J941, J949, J953, J961, J969,
J984, J988, J989, J99
OHIP dx: 491-494, 496, 501, 502, 515,
518, 519
OHIP fee: J889, J689
ICD-9: 4273
ICD-10: I48
ICD-9: 150, 154, 155, 157, 162, 174, 175,
185, 203-208, 2303, 2304, 2307, 2312,
2330, 2334
ICD-10: C15, C18-C20, C22, C25, C34,
C50, C56, C61, C82, C83, C85, C91-C95,
D00, D010-D012, D022, D05, D075, 971,
980, 982, 984-991, 993
OHIP dx: 203-208, 150, 154, 155, 157,
162, 174, 175, 183, 185
ICD-9: 303, 3050
ICD-10: E244, E512, F10, G312, G621,
G721, I426, K292, K70, K860, T510, X45,
X65, Y15, Y573, Z502, Z714, Z721
ICD-9: 345, 7803
ICD-10: G40, G41, R560, R568
ICD-9: 584
ICD-10: N17
ICD-9: 410
ICD-10: I21, I22
CCP: 0345-0349, 4971-4973, 4987
CCI: 1HD53GRJA, 1HD54GRJA, 1HD55,
1HZ09, 1HZ37, 1HZ53GRFR,
1HZ53GRNK, 1HZ53GRNL,
1HZ53GRNM, 1HZ53GRNN,
1HZ53LAFR, 1HZ53SYFR, 1HZ54LANJ,
1HZ55, 2HZ07NK, 2HZ07NL,
2HZ07NM, 2HZ24
OHIP fee: E628, G115, G176, G177,
G303, R752, Z412, Z428, Z433-Z435,
Z444-Z446
ICD-9: 2767
ICD-10: E875
ICD-9: 458
ICD-10: I95
ICD-9: 600
ICD-10: N40
OHIP dx: 600
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Prostatitis

CIHI-DAD

Acute urinary retention

OHIP
CIHI-DAD

Deep vein
thrombosis/Pulmonary
embolism
Health care use
GP/FP visits
Specialist consultations
Nephrologist consults

Dialysisb

CIHI-DAD

IPDB, OHIP

Mainspecialty = GP/FP

IPDB
OHIP

Mainspecialty = NEPHROLOGY
OHIP fee: A135, A161, A163-A166,
A168, C101, C132, C135, C137, C138,
E083, G323, G860
OHIP fee: G323, G325, G326, G330G332, G860-G866, R849
Mainspecialty = CARDIOLOGY

OHIP

Cardiologist consults
IPDB, OHIP
Prior investigations and treatments
Carotid ultrasound
CIHI-DAD
OHIP
Cardiac catheterization

ICD-9: 6010-6012
ICD-10: N410-N412
OHIP dx: 601
ICD-9: 7882
ICD-10: R33
ICD-9: 4151, 4511, 4512, 514
ICD-10: I26, I743, I801-I803

CIHI-DAD

OHIP
Coronary angiogram

CIHI-DAD

Echocardiography

OHIP
CIHI-DAD
OHIP

Electroencephalography

OHIP

Holter monitoring

CIHI-DAD
OHIP

CCP: 0281
CCI: 3JE30
OHIP fee: J190, J191, J201, J501, J189,
J489-J492
CCP: 4995-4997
CCI: 2HZ24GPKJ, 2HZ24GPKL,
2HZ24GPKM, 2HZ24GPXJ,
2HZ28GPPL, 2HZ71GP, 3HZ30GP,
3IJ30GP
OHIP fee: G296, G297, G299-G301,
G304-G306
CCP: 4892-4898, 4996, 4997
CCI: 3IP10
OHIP fee: G297, Z442
CCP: 0282
CCI: 3IP30
OHIP fee: G560-G562, G566-G568, G570G572, G574-G581
OHIP fee: G414-G418, G540, G542,
G544-G546, G554, G555
CCI: 2HZ24JAKH
OHIP fee: G650-G661, G682-G690, G692,
G693
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Cardiac stress test

CIHI-DAD

Cervical cancer
screening
Prostate-specific antigen
test
Mammography
Influenza vaccination
Bone mineral density
test

OHIP

CCP: 0341-0344
CCI: 2HZ08, 3IP70
OHIP fee: G111, G112, G174, G315,
G319, J604, J606-J609, J611-J613, J667,
J804, J807-J809, J811-J813, J666, J866,
J867
CCP: 480-483
CCI: 1IJ26, IIJ27, 1IJ50, 1IJ57, 1IJ76,
1IJ54GQAZ, 1IJ57GQ
OHIP fee: E646, E651, E652, E654, G262,
G298, R741-R743, Z434
CCI: 2HZ24JAKE
OHIP fee: G310, G313
OHIP fee: G004, L179, L181, Q043,
Q152, X112, X113, Z535, Z536, Z555,
Z580
OHIP fee: E430, G365, G394, L713, L812

OHIP

OHIP fee: L354, L358

OHIP
OHIP
OHIP

Hearing test

OHIP

Cystoscopy
Transurethral resection
of the prostate

OHIP
CIHI-DAD

OHIP fee: X172, X178, X184, X185, X201
OHIP fee: G590, G591
OHIP fee: J654, J688, J854, J888, X149,
X152, X153, X155, Y654, Y688, Y854,
Y888
OHIP fee: G153, G154, G440-G443,
G448, G450-G452, G525, G526, G529,
G530, G533, G815, G816
OHIP fee: Z606, Z607, Z628, Z632-Z634
CCP: 721
CCI: 1QT59BAAD, 1QT59BAAG,
1QT59BAAW, 1QT59BAAZ,
1QT59BACG, 1QT59BAGX, 1QT87BA,
1QT87BAAG, 1QT87BAAK
OHIP fee: S655
OHIP fee: X188, X400-X402, X405, X408

OHIP

Coronary
revascularization

CIHI-DAD
OHIP

Electrocardiography
Colorectal cancer
screening

Computed tomography
of head
Computed tomography
of other areas
Chest x-ray
Pulmonary function test

CIHI-DAD
OHIP
OHIP

OHIP
OHIP
OHIP
OHIP
OHIP

OHIP fee: X124-X128, X231-X233, X403,
X404, X406, X407, X409, X410, X412,
X413, X415, X416
OHIP fee: X090-X092, X195
OHIP fee: E450, E451, J301, J303-J311,
J313, J315-J320, J322-J324, J327, J328,
J330-J335, J340, J341
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At-home physician
services
Urinalysis

OHIP

Sputum

OHIP

OHIP

OHIP fee: A901, B960-B964, B966, B990,
B992-B994, B996-B998
OHIP fee: L253-L255, L633, L634, L641,
G009, G010
OHIP fee: L629, L716, L815

Abbreviations: CCI = Canadian Classification of Health Interventions (available after
2002), CCP = Canadian Classification of Diagnostic, Therapeutic and Surgical
Procedures (before 2002), CIHI-DAD = Canadian Institute for Health Information
Discharge Abstract Database, CORR = Canadian Organ Replacement Register, DSM-IV
= Diagnostic and Statistical Manual of Mental Disorders, 4th edition, GP/FP = general
practitioner/family practitioner, ICD-9 = International Classification of Diseases, Ninth
Revision, ICD-10 = International Classification of Diseases, Tenth Revision, IPDB =
Institute for Clinical Evaluative Sciences (ICES) Physician Database, LHIN = Local
Health Integration Network, ODB = Ontario Drug Benefit, OHIP = Ontario Health
Insurance Plan, OMHRS = Ontario Mental Health Reporting System, RPDB =
Registered Persons Database of Ontario
a
LHIN refers to health authorities responsible for regional administration of public
healthcare services in Ontario.
b
Only includes dialysis visits with nephrologist present.
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Appendix D. Coding definitions for hospital encounter with ventricular arrhythmia and
all-cause mortality
Outcome
Ventricular arrhythmia
All-cause mortalitya

Database
CIHI-DAD, NACRS
RPDB

Codes
ICD-10: I472, I4900
Vital status field

Abbreviations: CIHI-DAD = Canadian Institute for Health Information Discharge
Abstract Database, ICD-10 = International Classification of Diseases, Tenth Revision,
NACRS = National Ambulatory Care Reporting System, RPDB = Registered Persons
Database of Ontario
a
All-cause mortality has a sensitivity of 97.8% and specificity of 100% (70).
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Appendix E. Coding definitions for cause of death data in Ontario Registrar General
Vital Statistics Database
Cause of Death
Cardiovascular
Ischemic heart disease
Heart failure
Cerebrovascular
Arrhythmia
Valvular heart disease
Other

Infection
Abdominal

Cardiac
Kidney/genitourinary
Neurological
Respiratory

Septicemia

ICD-9 Codes
4019, 4020, 4100, 4110, 4120, 4130, 4140, 4141, 4148,
4149, 4230, 4292, 4298
3989, 4029, 4049, 4254, 4255, 4257-4259, 4280, 4281,
4289, 7798
430, 431, 435, 436, 438, 3448, 3623, 4320, 4321, 43294333, 4338-4341, 4349, 4370, 4372-4376, 4378, 4379
4260, 4261, 4267, 4269-4276, 4278, 4279, 4299, 7850,
7853, 9960, v450, v533
393, 3940-3942, 3949-3952, 3959, 3960, 3970, 3979,
3980, 3989, 4010, 4011, 4039, 4240-4243, 4249
4151, 4400-4402, 4408-4415, 4419-4423, 4428-4431,
4438-4442, 4448, 4449, 4470-4472, 4474-4476, 44784481, 4489, 7982, 7989, 9960
0020-0023, 0029-0032, 0038-0043, 0048, 0049, 00600066, 0068-0072, 0078-0080, 0084-0086, 0088, 0093, 541543, 0700-0703, 0705, 0706, 0709, 5400, 5401, 5409,
5740-5743, 5745, 5750-5756, 5758, 5759
4209, 4229
0900-0907, 0909-0913, 0919, 0929, 0939, 0943, 09480950, 0960, 0970, 0971, 0979, 5900, 5990
064, 0360, 0362-0364, 0368, 0369, 0620-0625, 0628-0630,
0632, 0638, 0639, 3200-3203, 3207-3210, 3218
0130, 0131, 0138-0140, 0159, 0169, 0170, 0172-0174,
0176, 0178, 0180, 0188, 0189, 0330, 0331, 0338, 0339,
483, 4660, 4661, 4787, 4800-4802, 4808-4810, 4820-4824,
4828, 4829, 4847, 4848, 4850, 4860, 4870, 4871, 4878,
5110, 5118-5120, 5140, 5172, 5178, 5180-5182, 5185,
5188, 5190, 5191, 5193, 5194, 5198, 5199, 7991, 9973
0380-0384, 0388, 0389
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Other

Cancer
Malignant

Non-malignant

0010, 0011, 0019, 0050-0052, 0054, 0058, 0059, 0101,
0200-0202, 0205, 0208-0210, 0220-0223, 0228-0233,
0238-0240, 0250, 0260, 0261, 0269-0272, 0278, 0279,
0300-0303, 0308-0311, 0318-0321, 0323, 0328, 0329,
0341, 0350, 0370, 0390-0393, 0398-0400, 0408, 04100419, 0429, 0451, 0452, 0459, 0461-0463, 0468, 0469,
0478-0480, 0490, 0491, 0498, 0499, 0509, 0519, 0520,
0530-0532, 0537, 0539-0547, 0549-0552, 0557, 0559,
0560, 0567, 0569, 0570, 0578, 0579, 0600, 0601, 0609,
0610, 0650-0652, 0654, 0658-0663, 0668, 0669, 0710,
0720-0723, 0727, 0729, 0730, 0740, 0741, 0743, 0750,
0760, 0761, 0769, 0771-0774, 0778-0781, 0783, 07850788, 0790, 0798-0800, 0810-0812, 0819-0822, 0823,
0829-0832, 0838-0844, 0846, 0849, 0850, 0855, 08590865, 0870, 0871, 0879, 0880, 0888, 0980, 0981, 09840988, 0990-0992, 0998-1000, 1008, 1009, 1020-1033,
1039, 1040, 1048, 1049, 1100-1105, 1108-1113, 11181125, 1128, 1129, 1140, 1150, 1151, 1159-1162, 11701172, 1174-1177, 1179, 1180, 1200-1203, 1208-1214,
1218-1221, 1223-1236, 1238-1240, 1250-1253, 12551257, 1259, 1261, 1268-1281, 1288-1290, 1300, 1310,
1318-1323, 1329, 1330, 1338, 1340-1342, 1348, 1349,
1362, 1363, 1368-1374, 1380, 1390, 1391, 1398, 3240,
4298, 6829, 7713
1400, 1401, 1403-1406, 1408-1414, 1416, 1418-1422,
1428-1431, 1439-1441, 1448-1456, 1458-1464, 14661473, 1478-1483, 1488-1491, 1498, 1500-1505, 15081516, 1518-1523, 1528-1543, 1548, 1550-1552, 15601562, 1568-1574, 1578-1580, 1588-1591, 1598-1605,
1608-1613, 1618-1620, 1622-1625, 1628, 1629, 16391643, 1648-1650, 1658, 1659, 1700-1710, 1712-1746,
1748, 1749, 1790, 1800, 1801, 1808-1810, 1820, 1821,
1828, 1830, 1832-1835, 1838-1844, 1848-1850, 1860,
1869, 1871-1894, 1898-1906, 1908-1923, 1928-1930,
1940, 1941, 1943-1946, 1948-1955, 1958, 1960-1963,
1965, 1966, 1968-1978, 1980-1988, 1990, 1991, 20002002, 2008, 2011, 2014-2017, 2019-2026, 2028-2031,
2038, 2040, 2041, 2048-2051, 2053, 2058-2060, 20682070, 2072, 2078, 2080, 2081, 2088, 2089, 2387, 2733,
2849, 2850, 2898
2100-2140, 2150, 2152-2157, 2159-2167, 2169, 2170,
2180, 2190, 2191, 2198-2200, 2210-2212, 2218-2224,
2228-2233, 2238-2246, 2249-2254, 2258-2260, 2270,
2271, 2273-2276, 2278-2281, 2290, 2298, 2299
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Other
Chronic lung disease
Diabetes
Neurological and
dementias

Digestive

Suicide and accidents
Other

1173, 4900, 4910-4912, 4918-4920, 4930, 4931, 4939,
4940, 4950-4960, 5000, 5010, 5020, 5030, 5040, 5050,
5163
2500-2502, 2504-2507, 2510
2900, 2901, 2904, 2908, 2909, 2940, 2941, 3030, 3078,
3220, 3222, 3229, 3234, 3235, 3238-3241, 3249, 3250,
3260, 3308, 3310-3314, 3317-3321, 3330-3342, 3344,
3348-3352, 3360-3363, 3368-3371, 3379, 3400, 3410,
3411, 3418-3421, 3429, 3430, 3432, 3434, 3438-3446,
3448-3455, 3457-3462, 3468-3470, 3480-3485, 34883490, 3492, 3498, 3499, 3501, 3502, 3508-3511, 35183520, 3522-3526, 3529-3536, 3538-3545, 3548-3559,
3561, 3563, 3564, 3568-3582, 3588-3596, 3598, 3599,
3886, 7428, 7805, 7807, 7840, 7860, 9958, 9970
2111, 2113, 5200-5236, 5238-5246, 5248-5253, 52585265, 5268-5280, 5282-5286, 5288-5296, 5298-5317,
5319-5327, 5329-5337, 5339-5347, 5349-5351, 53535356, 5361, 5368, 5370, 5371, 5373, 5374, 5376, 5378,
5379, 5500, 5501, 5509-5513, 5518-5523, 5528-5533,
5538, 5539, 5550-5552, 5559, 5560, 5570, 5571, 5579,
5580, 5600-5603, 5608, 5620, 5621, 5640-5643, 56455651, 5660, 5670, 5672, 5678-5680, 5688-5696, 56985700, 5710-5716, 5718-5721, 5723, 5724, 5728, 5730,
5732-5734, 5738, 5739, 5759-5765, 5768-5772, 57785781, 5789-5794, 5798, 5799, 9974
E000-E030, E800-E807, E810-E838, E840-E858, E860E876, E878-E888, E890-E999
Every other code
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Appendix F. Standard daily drug doses for the treatment of respiratory tract infections
Drug
Macrolide antibiotics
Azithromycin
Clarithromycin
Erythromycin
Non-macrolide antibiotics
Amoxicillin
Cefuroxime
Levofloxacin
a

Standard daily doses (mg)a
250 to 500
500 to 1,000
500 to 2,000
750 to 1,750
500 to 1,000
500 to 750

Prescriptions for any daily drug doses that are not standard for the treatment of
respiratory tract infections were excluded from our two groups to ensure generalizability
to usual prescribing.
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Appendix G. Variables included in the propensity score
Variables Included in the Propensity Score
Age
Sex
Neighbourhood income quintile
Demographics
Index date
Rural residence
Long-term care
Local Health Integration Network
Dementia
Schizophrenia or related psychotic disorder
Bipolar disorder
Unipolar depression and/or anxiety disorder
Haemorrhagic stroke
Ischemic stroke
Transient ischemic attack
Chronic liver disease
Chronic kidney disease
Congestive heart failure
Coronary artery disease
Angina
Peripheral vascular disease
Parkinson's disease
Chronic lung disease
Comorbidities
Atrial fibrillation/flutter
Cancer
Alcoholism
Seizure
Acute kidney injury
Acute myocardial infarction
Pacemaker
Hyperkalemia
Hypotension
Prostatic hyperplasia
Prostatitis
Acute urinary retention
Deep vein thrombosis/Pulmonary embolism
Charlson comorbidity index
Johns Hopkins Aggregated Diagnosis Groups

73

Medications

Health Care Use

Antiarrhythmic
Antipsychotic
Proton pump inhibitor
Antiemetic
Lithium
Antilipemic
Antihypertensive
Potassium sparing diuretic
Histamine H2-receptor antagonist
Prokinetic
QT-prolonging
Antidiabetic
Acetylsalicylic acid
Anticoagulant (excludes warfarin)
Antiplatelet
Tricyclic antidepressant
Opioid
Antimalarian
Antiviral
Antineoplastic
Benzodiazepine
Non-steroidal anti-inflammatory drug (excludes acetylsalicylic
acid)
Anticonvulsant
Angiotensin-converting enzyme inhibitor or angiotensin II
receptor blocker
Beta-adrenergic antagonist
Calcium channel blocker
Non-potassium sparing diuretic
Statin
Antiparkinson drug
Digoxin
Overactive bladder medication
Warfarin
Inhaler - acetylcholine
Inhaler - corticosteroid
Inhaler - beta-agonist
Smoking cessation aid
Number of any hospitalizations
Number of any emergency room visits
General practice/Family practice visit
Nephrology visit
Cardiology visit
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Investigations (a
surrogate marker of
health care access)

Other

Carotid ultrasound
Cardiac catheterization
Coronary angiogram
Echocardiography
Electroencephalography
Holter monitoring
Cardiac stress test
Coronary revascularization
Electrocardiography
Colorectal cancer screening
Cervical cancer screening
Prostate-specific antigen test
Mammography
Influenza vaccination
Bone mineral density test
Hearing test
Cystoscopy
Transurethral resection of the prostate
Computed tomography of the head
Computed tomography of other areas
Chest x-ray
Pulmonary function test
At-home physician service
Urinalysis
Sputum
Prescriber specialty
Number of medications (polypharmacy)
Baseline serum creatinine measurement
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Appendix H. QT-prolonging drugs included in subgroup analysis
Drug Name
Amiodarone hydrochloride
Amitriptyline
Amitriptyline
hydrochloride
Amitriptyline
hydrochloride &
perphenazine
Amoxapine
Amprenavir
Aripiprazole
Atazanavir
Chloroquine
Chloroquine diphosphate
Chlorpromazine
Chlorpromazine
hydrochloride
Cisapride
Cisapride monohydrate
Citalopram hydrobromide

Clomipramine
Clomipramine
hydrochloride
Darunavir
Desipramine hydrochloride

Drug Identification Numbers
00705934, 02036282, 02239835, 02240071, 02240604,
02242472, 02243836, 02245781, 02246194, 02364336
00016306
00016322, 00016330, 00016349, 00037400, 00037419,
00037427, 00335053, 00335061, 00335088, 00377872,
00377880, 00377899
00140651, 00176931, 00176966
00527084, 00527092, 00527106, 00527114, 02169886,
02169894, 02169908
02243541, 02243542, 02243543
02322374, 02322382, 02322390, 02322404, 02322412,
02322455
02248610, 02248611
00021261
00033642, 01912984, 02017539
00025151, 00025186, 01929968
00025178, 00025453, 00025461, 00025488, 00025496,
00025518, 00232157, 00232807, 00232823, 00232831,
00580988, 01929909, 01929917, 01929925, 01929933,
01929941, 01929976, 01929992
00836311, 00836338, 00836354, 02054817
09852913
02239607, 02239608, 02246056, 02246057, 02246594,
02246595, 02248010, 02248011, 02248050, 02248051,
02248170, 02248171, 02248944, 02251558, 02251566,
02252112, 02252120, 02275562, 02275570, 02285622,
02285630, 02293218, 02293226, 02301830, 02304686,
02304694, 02306239, 02306247, 02313405, 02313413,
02322781, 02322803, 02331950, 02331977, 02353660,
02353679, 02355256, 02355272, 02355280, 02371898,
02371901, 09852913
02040751, 02040778, 02040786, 02130165, 02130173
00324019, 00330566, 00402591, 02139340, 02139359,
02139367, 02230063, 02230064, 02230065, 02230256,
02244816, 02244817, 02244818
02284057, 02324016, 02324024, 02338432, 02393050
00010448, 00353868, 00353876, 00425265, 00776157,
01946242, 01946269, 01946277, 01948776, 01948784,
01948792, 01948806, 02024896, 02024918, 02024926,
02099128, 02099136, 02211947, 02211955, 02211963,
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Dextropropoxyphene
hydrochloride
Dextropropoxyphene
napsylate
Disopyramide
Disopyramide phosphate
Dolasetron mesylate
Domperidone
Domperidone maleate
Doxepin hydrochloride

Escitalopram oxalate
Flecainide acetate
Fosamprenavir calcium
Hydroxychloroquine
Hydroxychloroquine
sulfate
Imipramine
Imipramine hydrochloride
Indinavir sulfate
Lopinavir & ritonavir
Maprotiline hydrochloride
Mesoridazine besylate
Methadone
Methadone hydrochloride
Mexiletine
Mexiletine hydrochloride
Moxifloxacin
hydrochloride
Nelfinavir mesylate
Ondansetron

02216248, 02216256, 02216264, 02216272, 02223325,
02223333, 02223368
00151351
00261432
00382876, 00439363, 01989553, 01989561, 02224801,
02224828
00396370, 00396389, 00584231, 00619760, 01989545,
02030799, 02030802, 02030810, 02224836
02231378, 02231379
00642851, 00855820, 02157195
01912070, 02103613, 02230473, 02231477, 02236466,
02268078, 02350440, 02369206, 02403870
00024325, 00024333, 00024341, 00326925, 00400750,
00584274, 00842745, 00842753, 00842761, 00842788,
00842796, 00842818, 01913441, 01913468, 01913476,
02049996, 02050005, 02050013, 02050021, 02050048,
02050056, 02140071, 02140098, 02140101, 02140128,
02144123, 02144131, 02144158
02263238, 02263254
00628220, 00817147, 01966197, 01966200, 02275538,
02275546
02261545
02246691, 02252600
00033669, 01928287, 02017709
00377902, 00377929
00010464, 00010472, 00010480, 00021504, 00021512,
00021520, 00312797, 00326852, 00360201, 00377910
02229161, 02229196
02243643, 02243644, 02285533, 02312301
00360481, 00360503, 00360511, 00641855, 02158604,
02158612, 02158620, 02158639
00027448, 00027456, 00027464, 00027448, 00027456,
00027464
09850619, 09851771, 09852891
09857217, 09857218, 09857219, 09857220, 09857221,
09857223
00599956, 00599964, 02231690, 02231692
02230359, 02230360
02242965
02238617, 02238618, 02248761
02239372, 02239373
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Ondansetron hydrochloride

Ondansetron hydrochloride
dihydrate
Paroxetine
Paroxetine hydrochloride

Pimozide
Probucol
Procainamide
hydrochloride
Propafenone
Propafenone hydrochloride
Propoxyphene
hydrochloride
Protriptyline hydrochloride
Quetiapine fumarate

Quinidine gluconate
Quinidine
polygalacturonate
Quinidine sulfate
Ritonavir
Saquinavir mesylate
Sotalol

02229639, 02258188, 02258196, 02264056, 02264064,
02274310, 02274329, 02278529, 02278537, 02288184,
02288192, 02291967, 02296349, 02296357, 02297868,
02297876, 02305259, 02305267, 02306212, 02306220,
02312247, 02312255, 02313685, 02313693, 02371731,
02371758, 02376091, 02376105, 02389983, 02389991
02344440, 02344459
02262754, 02262762
01940473, 01940481, 02027887, 02240907, 02240908,
02240909, 02247751, 02247752, 02247811, 02247812,
02248012, 02248013, 02248014, 02248451, 02248452,
02248557, 02248558, 02254751, 02254778, 02269430,
02269449, 02282860, 02368870, 02368889, 02383284,
02383292
00313815, 00313823, 00573817, 02245432, 02245433
00749044
00029076, 00296031, 00353523, 00638676, 00638684,
00638692, 00639885, 00713325, 00713333, 00713341
02343053, 02343061
00603708, 00603716, 02243324, 02243325, 02243727,
02243728, 02245372, 02245373, 02294559, 02294575
00010081
00322741
02236951, 02236952, 02236953, 02240862, 02244107,
02284235, 02284243, 02284278, 02284286, 02296551,
02296578, 02296594, 02296608, 02299062, 02300184,
02300192, 02300206, 02300214, 02307804, 02307812,
02307839, 02307847, 02311704, 02311712, 02311747,
02311755, 02313901, 02313928, 02313936, 02313944,
02313995, 02314002, 02314010, 02314029, 02316080,
02316099, 02316110, 02316129, 02317893, 02317907,
02317931, 02321513, 02330415, 02330423, 02330458,
02330466, 02353164, 02353199, 02387794, 02387808,
02387824, 02390205, 02390213, 02390248, 02390256,
02395444, 02395452, 02395460, 02395479, 02395487,
02397102
00311731, 00704644
00026131
00004782, 00021733, 00023868, 00026883, 00094412,
00249580, 00346837, 00441740, 01913883
02229137, 02229145, 02241480, 02357593
02216965, 02239083, 02279320
02229778, 02229779, 02229780, 02234013, 02257858
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Sotalol hydrochloride

Thioridazine hydrochloride

Trimipramine
Trimipramine maleate

Ziprasidone hydrochloride

00483923, 00897272, 02084228, 02084236, 02163772,
02167794, 02170841, 02210428, 02230650, 02231181,
02231182, 02238326, 02238327, 02238415, 02270625,
02270633, 02368625
00027359, 00027375, 00027529, 00027537, 00027545,
00027553, 00037478, 00037486, 00037494, 00037508,
00238775, 00360198, 00360228, 00360236, 00360244,
00456063, 00456071, 00456098, 00456101, 00575119,
00575127, 00575135, 00575143, 00775320, 02229553
01940449, 01940457
00025828, 00025836, 00025844, 00025852, 00442437,
00740799, 00740802, 00740810, 00740829, 00761605,
00761613, 00761621, 00761648, 00761656, 01926284,
01926322, 01926330, 01926349, 01926357, 01940430,
02020602, 02020610, 02020629, 02070987
02298597, 02298600, 02298619, 02298627
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Appendix I. 30-day cause of death in matched cohort of patients prescribed macrolide
antibiotics (azithromycin, clarithromycin or erythromycin) compared to referent nonmacrolide antibiotics (amoxicillin, cefuroxime or levofloxacin)a

Cause of deathb

Macrolide
(n = 503,612)

Non-Macrolide
(n = 503,612)

Standardized
Differencec

Cardiovasculard
Infectione
Cancerf
Otherg

638 (0.13)
96 (0.02)
569 (0.11)
429 (0.09)

755 (0.15)
100 (0.02)
785 (0.16)
551 (0.11)

1%
0%
1%
1%

a

Data are presented as the number (percentage) of patients.
Cause of death was not available for 1,412 (0.3%) macrolide antibiotic users and 1,642
(0.3%) non-macrolide antibiotic users in the matched cohort.
c
Standardized differences are less sensitive to sample size than traditional hypothesis
tests. They provide a measure of the difference between groups divided by the pooled
standard deviation; a value greater than 10% (0.1) is interpreted as a meaningful
difference between the groups (71).
d
Cardiovascular included death by ischemic heart disease, heart failure, cerebrovascular,
arrhythmia and valvular heart disease.
e
Infection type included abdominal, cardiac, kidney/genitourinary, neurological,
respiratory and septicemia.
f
Both malignant and non-malignant cancers were considered.
g
Other causes of death included chronic lung disease, diabetes, neurological and
dementias, digestive, suicide and accidents.
b
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Appendix J. 14-day risk for hospital encounter with ventricular arrhythmia and all-cause
mortality in matched cohort of patients prescribed macrolide antibiotics compared to
referent non-macrolide antibiotics

Outcome
Ventricular
arrhythmiaa
All-cause
mortality

Events, n (%)
Macrolide
Non-Macrolide
(n = 503,612)
(n = 503,612)

Relative Risk
(95% CI)

P value

71 (0.01)

72 (0.01)

0.99 (0.71-1.37)

0.93

1,687 (0.34)

2,061 (0.41)

0.82 (0.77-0.87)

< 0.0001

Abbreviations: CI = confidence interval
a
Based on hospital presentation (emergency room or hospitalization) assessed by
hospital diagnosis codes. This method of assessment underestimated the true number of
events as ventricular arrhythmias frequently go undetected in routine healthcare
(because they often occur outside hospital settings, in unmonitored patients in hospital
or in a setting of multi-organ medical illness where recorded codes describe other
illnesses besides the ventricular arrhythmia).
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